{"meta":{"query_hash":"c17a046801e7","filters":{"venue":"Therapeutic Advances in Neurological Disorders"},"cohort_total":60,"direct_labels_cover":0,"predictions_cover":60,"exported":60,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c17a046801e7","api":"https://metacan.xera.ac/api/v1/cohort?venue=Therapeutic+Advances+in+Neurological+Disorders"},"results":[{"id":"W145182321","doi":"10.1177/1756285608098359","title":"Review: Escalating immunotherapy of multiple sclerosis","year":2008,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Natalizumab; Glatiramer acetate; Alemtuzumab; Multiple sclerosis; Mitoxantrone; Immunotherapy; Clinical trial; Disease; Intensive care medicine; Fingolimod; Oncology; Immunosuppression; Immunology; Internal medicine; Transplantation; Chemotherapy; Immune system","score_opus":0.08269379223139042,"score_gpt":0.33855184917256637,"score_spread":0.2558580569411759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W145182321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6556073,0.33665085,0.0007108775,0.0028316658,0.0000962487,0.0014733303,0.0000072224084,0.00011515941,0.0025073702],"genre_scores_gemma":[0.56919247,0.4279246,0.0005259254,0.0022476474,0.0000127447765,0.00006721311,0.0000024818512,0.000014473093,0.0000124440485],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99803126,0.00020854098,0.0005398525,0.00038800316,0.00039240118,0.00043994136],"domain_scores_gemma":[0.99862176,0.0007292136,0.00014169874,0.0003656647,0.00006826252,0.00007339762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026408085,0.00022457953,0.0006598866,0.00010548376,0.000105403655,0.0000022698941,0.00021583597,0.00007624721,0.00014972374],"category_scores_gemma":[0.0006525566,0.00016277953,0.00018372691,0.00050616806,0.00068614277,0.00013137357,0.00008062406,0.0003933916,0.000009608471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089649344,0.00068513636,0.5399066,0.0005049542,0.00004822669,0.000008585545,0.0001937705,0.00017846933,0.007833459,0.00003964134,0.000081273996,0.44962335],"study_design_scores_gemma":[0.0036152087,0.001172282,0.9696761,0.00073116797,0.000020186002,0.000013209262,0.00004956846,0.0014638358,0.0003087946,0.00054232887,0.022173868,0.0002334739],"about_ca_topic_score_codex":0.000016473607,"about_ca_topic_score_gemma":0.000020584523,"teacher_disagreement_score":0.44938987,"about_ca_system_score_codex":0.000015645177,"about_ca_system_score_gemma":0.000025718111,"threshold_uncertainty_score":0.66379565},"labels":[],"label_agreement":null},{"id":"W1969905648","doi":"10.1177/1756285609336548","title":"Implementation of computer-based language therapy in aphasia","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Neurobiology of Language and Bilingualism","field":"Neuroscience","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Stroke Network","keywords":"Aphasia; Medicine; Intervention (counseling); Comprehension; Speech therapy; Audiology; Psychiatry; Linguistics","score_opus":0.022293370639712522,"score_gpt":0.34921015492106594,"score_spread":0.3269167842813534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969905648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967123,0.0010892628,0.0004962393,0.00095579977,0.00009548696,0.000355237,0.00000406462,0.000053445525,0.00023811274],"genre_scores_gemma":[0.988319,0.0009857448,0.00015948658,0.010494765,0.00001783203,0.000011246704,0.000002808472,0.0000073208175,0.0000018379814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985047,0.00033684255,0.00032101767,0.00040107314,0.00013203015,0.00030431888],"domain_scores_gemma":[0.99932104,0.000354839,0.00010951831,0.0001827028,0.0000063878733,0.000025484576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001322743,0.0001613026,0.00023511276,0.00014502184,0.000027719689,0.0000069733474,0.0002945444,0.00006672687,0.00007782124],"category_scores_gemma":[0.000027807951,0.00012432023,0.00006104922,0.00037272417,0.00017916507,0.00012345848,0.000016303637,0.00021060351,0.0000025400564],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031864297,0.00047137652,0.015996307,0.000005742486,8.751486e-7,0.00020717092,0.00058173196,0.0010552277,0.08418679,0.00048039205,0.0000010879448,0.89669466],"study_design_scores_gemma":[0.028019927,0.028243659,0.5336454,0.00007592872,0.00002323585,0.00018195924,0.0020505567,0.009728924,0.30147907,0.088808894,0.00563879,0.00210365],"about_ca_topic_score_codex":0.000013819832,"about_ca_topic_score_gemma":0.00009656558,"teacher_disagreement_score":0.89459103,"about_ca_system_score_codex":0.0000052772707,"about_ca_system_score_gemma":0.000014657896,"threshold_uncertainty_score":0.5069632},"labels":[],"label_agreement":null},{"id":"W2050439782","doi":"10.1177/1756285608101378","title":"Review: Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Dopaminergic; Dopamine; Levodopa; Medicine; Neuroscience; Parkinson's disease; Stimulation; Dopamine receptor; Dopaminergic pathways; Disease; Pharmacology; Psychology; Internal medicine","score_opus":0.022206452307059622,"score_gpt":0.3253167809701142,"score_spread":0.30311032866305454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050439782","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4424739,0.49786773,0.0033681942,0.046910945,0.00026199748,0.0071065137,0.000030955252,0.00030949755,0.0016702814],"genre_scores_gemma":[0.8480723,0.104132466,0.0001821098,0.047175713,0.000021265803,0.00030938894,0.000043143842,0.000018405432,0.000045205834],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979852,0.0001784539,0.0004739621,0.0006434563,0.00019879133,0.00052013056],"domain_scores_gemma":[0.9990431,0.00034522582,0.000111318885,0.00032028017,0.000033400647,0.00014669684],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016325552,0.00032423524,0.00058170845,0.00013420923,0.00006911532,0.000012126886,0.00016301384,0.00010321247,0.000069913345],"category_scores_gemma":[0.00015389165,0.00023497557,0.00019976552,0.00044906966,0.00014103485,0.00016251065,0.00001864574,0.00029501383,0.000009530048],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054857787,0.00500875,0.27912968,0.00032360957,0.000029831479,0.00013464894,0.000032749136,0.004123034,0.00011119521,0.0061120973,0.00014095106,0.69936764],"study_design_scores_gemma":[0.0054163933,0.0034581767,0.6729193,0.00018197292,0.0001407445,0.000002973994,0.000010614366,0.004475116,0.0000018962555,0.25847784,0.054604832,0.00031015152],"about_ca_topic_score_codex":0.0000019826614,"about_ca_topic_score_gemma":0.000014807899,"teacher_disagreement_score":0.6990575,"about_ca_system_score_codex":0.000021352247,"about_ca_system_score_gemma":0.000023745606,"threshold_uncertainty_score":0.95820254},"labels":[],"label_agreement":null},{"id":"W2085475081","doi":"10.1177/1756285609102724","title":"Review: Therapy for Alzheimer's disease: how effective are current treatments?","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Cholinesterase and Neurodegenerative Diseases","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Memantine; Medicine; Tolerability; Disease; Rivastigmine; Alzheimer's disease; Cholinesterase; Neurotransmitter receptor; Intensive care medicine; Pharmacology; Donepezil; Internal medicine; Dementia; Receptor; Adverse effect","score_opus":0.03884627347654957,"score_gpt":0.3714684075139778,"score_spread":0.33262213403742824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085475081","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18296412,0.7988388,0.00036795752,0.013640461,0.00016852315,0.0038209795,0.00004112614,0.000098820135,0.000059235044],"genre_scores_gemma":[0.6232785,0.35317096,0.000024695555,0.02278031,0.00008172765,0.000586197,0.00005042427,0.00001723116,0.000009955581],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99842095,0.00019443124,0.00022555715,0.0006031609,0.00018396672,0.00037195222],"domain_scores_gemma":[0.9990456,0.00028448316,0.000117914315,0.00031503668,0.000055580305,0.00018135204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007111325,0.0003457466,0.0005191137,0.000070254835,0.00008106087,0.000014725092,0.00013129812,0.000045136774,0.00002531224],"category_scores_gemma":[0.00011838117,0.0002311298,0.00028191076,0.00023983109,0.000116210525,0.0001763466,0.000012995535,0.00019613517,0.0000040651457],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003768738,0.0021930772,0.037482418,0.00014348146,0.000050235943,0.000024221876,0.000018815568,0.00004069631,0.0001119465,0.00014823445,0.00031391185,0.9557042],"study_design_scores_gemma":[0.008043831,0.0052823042,0.7360031,0.00069711823,0.0006107698,0.000008375379,0.000014315254,0.00040099904,0.00017461539,0.010776139,0.23745319,0.0005352351],"about_ca_topic_score_codex":1.9437506e-7,"about_ca_topic_score_gemma":0.0000016804129,"teacher_disagreement_score":0.95516896,"about_ca_system_score_codex":0.000012571506,"about_ca_system_score_gemma":0.000023895893,"threshold_uncertainty_score":0.94251996},"labels":[],"label_agreement":null},{"id":"W2103958324","doi":"10.1177/1756285611406166","title":"Therapeutic potential of melatonin and its analogs in Parkinson’s disease: focus on sleep and neuroprotection","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Circadian rhythm and melatonin","field":"Neuroscience","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brock University; University of Toronto; Centre for Addiction and Mental Health","funders":"Universidad de Buenos Aires; Consejo Nacional de Investigaciones Científicas y Técnicas","keywords":"Melatonin; Neuroprotection; Parkinson's disease; Medicine; Substantia nigra; Agomelatine; Circadian rhythm; Disease; Neuroscience; Melatonin receptor; REM sleep behavior disorder; Sleep (system call); Pharmacology; Internal medicine; Psychology; Hippocampus; Antidepressant","score_opus":0.024218408577794403,"score_gpt":0.252517391484598,"score_spread":0.22829898290680362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103958324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98763925,0.010209356,0.00021641796,0.00041445636,0.00015265738,0.00055304973,0.000006718899,0.000048303053,0.00075979606],"genre_scores_gemma":[0.9881613,0.010831632,0.0000149501475,0.0008908638,0.000012368244,0.000058084297,3.6469243e-7,0.000022254886,0.000008128126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99799657,0.0003977248,0.00032294806,0.0006818836,0.00020899838,0.00039184897],"domain_scores_gemma":[0.9993323,0.00022757734,0.00011868572,0.00019624675,0.0000086442815,0.00011651414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014617799,0.0002475059,0.0002908627,0.0002166876,0.00007273859,0.0000122027695,0.00017225972,0.00010470028,0.00004337963],"category_scores_gemma":[0.000100299076,0.00020579898,0.000052868672,0.00037999888,0.000352378,0.00024186316,0.00006124801,0.00040138653,0.000004283804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005541373,0.0013821452,0.21310285,0.000116424606,0.000014081428,0.0003290113,0.0010749197,0.0015419583,0.024640601,0.13304964,4.2688168e-7,0.61920655],"study_design_scores_gemma":[0.001554091,0.0010992069,0.9083536,0.00002187064,0.000020928233,0.000024572344,0.00003659991,0.0077351695,0.0054869573,0.07431838,0.0010391244,0.00030948748],"about_ca_topic_score_codex":0.000008976092,"about_ca_topic_score_gemma":0.000027630955,"teacher_disagreement_score":0.69525075,"about_ca_system_score_codex":0.000008313735,"about_ca_system_score_gemma":0.000011356308,"threshold_uncertainty_score":0.8392239},"labels":[],"label_agreement":null},{"id":"W2131043834","doi":"10.1177/1756285613476127","title":"Diagnosis and treatment of impulse control disorders in patients with movement disorders","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Impulse control; Medicine; Movement disorders; Impulsivity; Psychiatry; Parkinson's disease; Amantadine; Parkinsonism; Impulse control disorder; Antipsychotic; Disease; Internal medicine; Pathological; Schizophrenia (object-oriented programming)","score_opus":0.007107237729423374,"score_gpt":0.24302662833616773,"score_spread":0.23591939060674436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131043834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917875,0.0041480777,0.00013382535,0.0011274006,0.000046055557,0.002405729,0.000018957611,0.000030312878,0.0003021349],"genre_scores_gemma":[0.980906,0.017123185,0.000120431956,0.00081495935,0.0000053287254,0.0009789277,0.000015812044,0.000026709682,0.000008623117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99835134,0.000108484404,0.00033988568,0.00051106233,0.00025377545,0.0004354537],"domain_scores_gemma":[0.9992937,0.00018552375,0.000115067385,0.0002467021,0.000021274209,0.00013777368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000039780418,0.00034118377,0.00054278027,0.00015255161,0.00004176959,0.000009674466,0.00008407,0.00008210757,0.00013727091],"category_scores_gemma":[0.000016773089,0.00021964025,0.000084932995,0.00023929692,0.00023731645,0.00018474415,0.000022680086,0.00010374904,0.000004650679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096994254,0.0032963087,0.64125943,0.000017304697,0.000050322753,0.0000021107953,0.0000631817,0.00016809671,0.00000319635,0.00008419663,4.703965e-7,0.35408548],"study_design_scores_gemma":[0.0161216,0.006860541,0.9592372,0.00002562779,0.00008534696,1.5685333e-7,0.00007129662,0.00048064586,0.0000068456525,0.015511677,0.0014041304,0.00019490725],"about_ca_topic_score_codex":0.00017831926,"about_ca_topic_score_gemma":0.00074586755,"teacher_disagreement_score":0.35389057,"about_ca_system_score_codex":0.000041280535,"about_ca_system_score_gemma":0.000017052269,"threshold_uncertainty_score":0.89566696},"labels":[],"label_agreement":null},{"id":"W2163670346","doi":"10.1177/1756285610391693","title":"Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple sclerosis; Expanded Disability Status Scale; Internal medicine; Interferon beta-1a; Placebo; Randomized controlled trial; Gastroenterology; Quartile; Confidence interval; Interferon beta; Immunology; Pathology","score_opus":0.1420817650018123,"score_gpt":0.3665192244154442,"score_spread":0.2244374594136319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163670346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966894,0.0007663073,0.00010977393,0.00012501032,0.00010281131,0.0020917058,0.000018319524,0.000046231635,0.000050457842],"genre_scores_gemma":[0.99878323,0.00042082492,0.00012359617,0.0003811562,0.000012867396,0.00022853083,0.000008112574,0.000037560672,0.00000411799],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969512,0.0005886358,0.0006252887,0.0006601486,0.00064053567,0.0005341924],"domain_scores_gemma":[0.99779826,0.0011489026,0.00020736788,0.00063872105,0.000092031776,0.000114716415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003307248,0.00040370304,0.0008404436,0.0002089429,0.000092587834,0.000014355702,0.0004394278,0.00008650582,0.000052817068],"category_scores_gemma":[0.0005451067,0.00020459219,0.00018617565,0.00054057373,0.00029673244,0.00020872247,0.00020728618,0.00059381936,0.000005238439],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011654885,0.003389635,0.94842994,0.000011408593,0.00024851898,0.000005088903,0.004974636,0.00048992736,0.00021116306,8.322813e-7,0.000001644258,0.030582312],"study_design_scores_gemma":[0.0079536745,0.019469185,0.97079664,0.00017844104,0.000072859606,6.283792e-8,0.0012198336,0.000027168699,0.000046866506,0.000042390915,0.0000014882813,0.0001914046],"about_ca_topic_score_codex":0.0001641677,"about_ca_topic_score_gemma":0.0014678754,"teacher_disagreement_score":0.030390907,"about_ca_system_score_codex":0.000060916336,"about_ca_system_score_gemma":0.000026182364,"threshold_uncertainty_score":0.8343027},"labels":[],"label_agreement":null},{"id":"W2167117206","doi":"10.1177/1756285614546855","title":"Teriflunomide in the treatment of multiple sclerosis: current evidence and future prospects","year":2014,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Fungal Plant Pathogen Control","field":"Agricultural and Biological Sciences","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Tolerability; Context (archaeology); Clinical trial; Intensive care medicine; Relapsing remitting; Alternative medicine; Investigational Drugs; Adverse effect; Pharmacology; Internal medicine; Fingolimod; Immunology; Pathology","score_opus":0.06633268888999329,"score_gpt":0.29722541186729146,"score_spread":0.23089272297729818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167117206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016221792,0.9815152,0.0000010543702,0.00033757326,0.00017304055,0.0016573053,0.000044001135,0.000021138543,0.000028884477],"genre_scores_gemma":[0.05891248,0.9403385,0.000008651152,0.00013149636,0.00018436374,0.00040171697,0.000018707273,0.0000025352242,0.0000015424338],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974633,0.0007903715,0.0005629543,0.0006060176,0.00020510868,0.00037227693],"domain_scores_gemma":[0.99671793,0.0028016916,0.00028576786,0.00014131932,0.000010477113,0.000042833963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002815285,0.0004300871,0.0011560895,0.00003073403,0.000063574764,0.00003116986,0.00053341826,0.00019087929,0.000016927239],"category_scores_gemma":[0.00005982276,0.00012301891,0.00023335668,0.00040442884,0.00019092287,0.00011688244,0.000039036277,0.0003198503,0.0000039472807],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000076828204,0.0003561786,0.0032265885,0.00043133256,0.0000051508855,0.000003272508,0.000046152807,0.0000031974423,0.000028512935,0.00008287805,6.805376e-7,0.9957392],"study_design_scores_gemma":[0.00029865216,0.0017969134,0.019875845,0.001038096,0.000075992386,0.0000062267145,0.000029257593,0.000039183353,4.636536e-7,0.0005066141,0.97607654,0.00025621854],"about_ca_topic_score_codex":0.000010482912,"about_ca_topic_score_gemma":0.0007361214,"teacher_disagreement_score":0.995483,"about_ca_system_score_codex":0.00001786869,"about_ca_system_score_gemma":0.000009216037,"threshold_uncertainty_score":0.5016566},"labels":[],"label_agreement":null},{"id":"W2168568690","doi":"10.1177/1756285614549554","title":"Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome","year":2014,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Bayer HealthCare","keywords":"Medicine; Multiple sclerosis; Clinically isolated syndrome; Interferon beta-1b; Placebo; Expanded Disability Status Scale; Magnetic resonance imaging; Internal medicine; McDonald criteria; Randomization; Clinical trial; Interferon beta-1a; Interferon beta; Gastroenterology; Pathology; Immunology; Radiology","score_opus":0.2568097306530227,"score_gpt":0.4393229827033321,"score_spread":0.18251325205030938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168568690","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.048852127,0.94221085,0.0009057102,0.0010735212,0.00011622336,0.006731531,0.000055311673,0.000030978226,0.000023769522],"genre_scores_gemma":[0.40917745,0.5893065,0.00038079006,0.00035584572,0.000012429775,0.0007111016,0.000011412913,0.000042644202,0.0000018605629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9917204,0.002202445,0.003570168,0.0009947864,0.00070056244,0.00081164425],"domain_scores_gemma":[0.92428124,0.07305861,0.0014226635,0.0010244614,0.00012349298,0.00008954343],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004847094,0.0006745897,0.003674199,0.00037682801,0.00009620704,0.000020375028,0.0014307467,0.00045384298,0.000020249716],"category_scores_gemma":[0.009187701,0.00031973672,0.0006931429,0.0013352738,0.0018963335,0.00012997907,0.0004547982,0.00207495,0.0000037064522],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062251817,0.001118941,0.17896594,0.0038994546,0.0003132834,0.000005544709,0.00020151398,0.000649119,0.0000011882624,0.000028681005,0.00000261178,0.80858856],"study_design_scores_gemma":[0.026651287,0.05870954,0.75204897,0.10233342,0.002882443,0.0000641313,0.00051603524,0.006618444,6.4069127e-7,0.001330623,0.047143318,0.0017011617],"about_ca_topic_score_codex":0.00004204284,"about_ca_topic_score_gemma":0.000455986,"teacher_disagreement_score":0.8068874,"about_ca_system_score_codex":0.000047830814,"about_ca_system_score_gemma":0.00024373425,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W2405578566","doi":"10.1177/1756285616648060","title":"Quantitative analysis of multiple sclerosis patients’ preferences for drug treatment: a best–worst scaling study","year":2016,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; University of Saskatchewan; Sunnybrook Hospital; Memorial University of Newfoundland; University of British Columbia","funders":"","keywords":"Medicine; Adverse effect; Multiple sclerosis; Drug; Preference; Latent class model; Logistic regression; Pharmacotherapy; Intensive care medicine; Internal medicine; Pharmacology; Psychiatry; Machine learning; Statistics","score_opus":0.12485522937899911,"score_gpt":0.37362392206675404,"score_spread":0.24876869268775492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2405578566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942565,0.0017271508,0.0011325662,0.00038888745,0.000051892806,0.0021943704,0.0000942097,0.000038796014,0.00011563721],"genre_scores_gemma":[0.989614,0.009101178,0.00051438063,0.00008230246,0.000009845053,0.0006233689,0.000012000598,0.000017906252,0.000025009316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99772894,0.0002998466,0.0005229354,0.0006084162,0.00038967165,0.0004501954],"domain_scores_gemma":[0.9958721,0.003404782,0.00018318491,0.00030549307,0.00014794643,0.000086507396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024199035,0.00027587393,0.000859395,0.0003852594,0.00010804518,0.000008893566,0.00019908028,0.00005586598,0.000052085863],"category_scores_gemma":[0.00085933163,0.00014679934,0.00027842412,0.0008873559,0.00045571753,0.00016522393,0.00006992221,0.000097603974,0.0000030917313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026759366,0.0033223042,0.77010643,0.000021435251,0.0006426023,4.6339414e-7,0.0008964444,0.00029834322,0.00033620116,0.000037071193,7.8053597e-7,0.221662],"study_design_scores_gemma":[0.0077674114,0.008522354,0.9775127,0.000056323188,0.00069007056,3.216607e-8,0.0014048973,0.0028628572,0.00008757804,0.00067437685,0.00024801234,0.00017338645],"about_ca_topic_score_codex":0.0000745233,"about_ca_topic_score_gemma":0.001520903,"teacher_disagreement_score":0.22148861,"about_ca_system_score_codex":0.00004180279,"about_ca_system_score_gemma":0.00002042851,"threshold_uncertainty_score":0.5986303},"labels":[],"label_agreement":null},{"id":"W2737414819","doi":"10.1177/1756285617722352","title":"Liver injury and glatiramer acetate, an uncommon association: case report and literature review","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Drug-Induced Hepatotoxicity and Protection","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alberta Innovates - Health Solutions; Biogen; Sanofi","keywords":"Medicine; Glatiramer acetate; Autoimmune hepatitis; Discontinuation; Liver injury; Magnetic resonance imaging; Liver function; Lesion; Multiple sclerosis; Liver biopsy; Past medical history; Hepatitis; Radiology; Gastroenterology; Internal medicine; Surgery; Biopsy; Immunology","score_opus":0.17526836751665378,"score_gpt":0.49953015378177357,"score_spread":0.3242617862651198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2737414819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007464889,0.99513626,0.000011889444,0.00043814586,0.0007043032,0.001810786,0.000058368925,0.00008419875,0.0010095602],"genre_scores_gemma":[0.0011677707,0.99526745,0.000046964567,0.0027443357,0.0001389695,0.00032348122,0.00006001261,0.000041498188,0.00020951987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511683,0.0025734063,0.0007736964,0.0008715448,0.00017508931,0.00048943434],"domain_scores_gemma":[0.9974746,0.0008710623,0.00094989926,0.00046000993,0.00005173112,0.00019267996],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001557905,0.0006059234,0.0015575689,0.00013972246,0.00046552432,0.000082939456,0.00030899083,0.0012842682,0.0000876886],"category_scores_gemma":[0.00035387825,0.00047066505,0.00019380805,0.00028018892,0.00033813494,0.0005542052,0.00016584227,0.0031568801,0.000009725314],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006725908,0.00014055712,0.0004851372,0.0077735214,0.00007628931,0.0067113745,0.00008494097,0.0000025762427,2.8191602e-7,0.000115442286,0.000025311278,0.98451734],"study_design_scores_gemma":[0.00035574246,0.00033181798,0.000075991455,0.0024943496,0.00057880103,0.008825881,0.000005654408,0.0000856431,2.5789822e-7,0.0021000367,0.98466784,0.00047799925],"about_ca_topic_score_codex":0.000010082046,"about_ca_topic_score_gemma":0.00011524032,"teacher_disagreement_score":0.9846425,"about_ca_system_score_codex":0.00004980609,"about_ca_system_score_gemma":0.000051476025,"threshold_uncertainty_score":0.9997745},"labels":[],"label_agreement":null},{"id":"W2804885025","doi":"10.1177/1756286418774338","title":"Phase IV study of retention on fingolimod <i>versus</i> injectable multiple sclerosis therapies: a randomized clinical trial","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Fingolimod; Medicine; Multiple sclerosis; Randomized controlled trial; Natalizumab; Relapsing remitting; Clinical trial; Internal medicine; Oncology; Immunology","score_opus":0.1835123173007922,"score_gpt":0.42967258634070865,"score_spread":0.24616026903991645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2804885025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990807,0.0010636641,0.00042112064,0.00058134925,0.0006414575,0.0052794176,0.000007708417,0.00009881994,0.0010994525],"genre_scores_gemma":[0.98877436,0.009500186,0.00018083032,0.00070595753,0.0002069252,0.00057118636,0.0000062437757,0.000033136595,0.000021182705],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9944722,0.0022063183,0.001215347,0.00080449466,0.0007286344,0.0005729898],"domain_scores_gemma":[0.9925968,0.006178096,0.0003550371,0.00059697445,0.0001471696,0.00012594559],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002292452,0.0003530223,0.0014895797,0.00022188196,0.00016522188,0.000017612494,0.0003198717,0.0001707392,0.00014520556],"category_scores_gemma":[0.0045729815,0.00023613489,0.0003921394,0.00059426064,0.0015228641,0.00016612854,0.00013592787,0.000632512,0.000015131197],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8281413,0.014821608,0.006475265,0.000022690057,0.00022858477,0.0000028537036,0.0007483949,0.00003771679,0.0003434905,0.000052444786,0.000016232238,0.14910944],"study_design_scores_gemma":[0.9073664,0.07384894,0.010506646,0.000057707904,0.0001407078,3.4043322e-7,0.0008935821,0.004989859,0.000048574628,0.0006809984,0.0012542756,0.00021198754],"about_ca_topic_score_codex":0.000043037024,"about_ca_topic_score_gemma":0.00021725478,"teacher_disagreement_score":0.14889745,"about_ca_system_score_codex":0.000023975015,"about_ca_system_score_gemma":0.000039209233,"threshold_uncertainty_score":0.96293014},"labels":[],"label_agreement":null},{"id":"W2889307958","doi":"10.1177/1756286418791143","title":"Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; McGill University; London Health Sciences Centre; NeuroRx Research (Canada)","funders":"Genentech; Biogen","keywords":"Medicine; Tolerability; Multiple sclerosis; Dosing; Adverse effect; Clinical endpoint; Internal medicine; Incidence (geometry); Surgery; Clinical trial","score_opus":0.12081327884060752,"score_gpt":0.3691826571197619,"score_spread":0.24836937827915437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889307958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865677,0.0056035016,0.00018448658,0.0054157893,0.0001932483,0.0017631768,0.00003257227,0.00006027699,0.00017927469],"genre_scores_gemma":[0.98958653,0.008263048,0.00017467812,0.0017079246,0.00006393537,0.00014174612,0.000012033426,0.000029780182,0.000020351259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651605,0.0005858306,0.0008301297,0.0008525653,0.00059940235,0.0006160362],"domain_scores_gemma":[0.9955911,0.0031595537,0.00021989777,0.0008525998,0.00010449592,0.00007234924],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006409251,0.00036084888,0.00081142306,0.00013486519,0.0001292484,0.000014594645,0.0005297835,0.00010449068,0.00005147307],"category_scores_gemma":[0.0014974355,0.00021095468,0.00014185543,0.00049203663,0.0011907415,0.00020213462,0.0003400399,0.00059569435,0.000015997444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006266601,0.0013977742,0.85488105,0.000014991474,0.00005327897,0.000012678109,0.001189117,0.00015259798,0.0010827116,0.000008292235,0.000008600647,0.1349323],"study_design_scores_gemma":[0.007881563,0.003231503,0.98627853,0.00012961212,0.000034371642,7.0843686e-7,0.00053706864,0.0008218404,0.00011002751,0.00031976894,0.00047108106,0.00018393584],"about_ca_topic_score_codex":0.00017448649,"about_ca_topic_score_gemma":0.004638803,"teacher_disagreement_score":0.13474835,"about_ca_system_score_codex":0.00003343064,"about_ca_system_score_gemma":0.000022227025,"threshold_uncertainty_score":0.8602482},"labels":[],"label_agreement":null},{"id":"W2889527974","doi":"10.1177/1756286418795085","title":"Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Biogen","keywords":"Medicine; Multiple sclerosis; Predictive value; Clinical disease; Magnetic resonance imaging; Internal medicine; Disease; Cardiology; Gastroenterology; Radiology; Immunology","score_opus":0.06831757290086274,"score_gpt":0.3485683056196654,"score_spread":0.28025073271880263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889527974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931571,0.005282903,0.000039850085,0.00044435388,0.000042561158,0.0009895626,0.0000065268046,0.000011122422,0.000026049456],"genre_scores_gemma":[0.98966753,0.009636345,0.00018056853,0.0003982572,0.0000142601375,0.00008601738,0.0000012268564,0.000013673692,0.0000021307746],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778247,0.0005318524,0.0003801453,0.0004436586,0.0004976449,0.00036425833],"domain_scores_gemma":[0.9971465,0.002199446,0.00018917161,0.00031939594,0.00009590408,0.000049598722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006236976,0.00021311783,0.0004927041,0.00014510634,0.000049496386,0.0000053165977,0.00020373079,0.000046103087,0.0000072911507],"category_scores_gemma":[0.0016093326,0.00013418471,0.000047513968,0.00041839125,0.0013521749,0.0002807895,0.00018408989,0.00034949786,6.0115366e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021246044,0.0009169514,0.9478219,0.0002460304,0.00002780856,0.0000027304425,0.0008254411,0.000111674875,0.00079066656,0.0000067310857,0.0000021074202,0.028001882],"study_design_scores_gemma":[0.00392135,0.004646429,0.9889557,0.0010527489,0.000021638925,1.0571309e-7,0.0003175642,0.00073688093,0.000033529654,0.00015594746,0.000039492406,0.000118609],"about_ca_topic_score_codex":0.00007174498,"about_ca_topic_score_gemma":0.00044638818,"teacher_disagreement_score":0.041133773,"about_ca_system_score_codex":0.000045652854,"about_ca_system_score_gemma":0.000025190931,"threshold_uncertainty_score":0.54718935},"labels":[],"label_agreement":null},{"id":"W2899137047","doi":"10.1177/1756286418804760","title":"Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure","year":2018,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Novartis Pharma; IC Design Education Center; Biogen; Ipsen; Novartis","keywords":"Fingolimod; Medicine; Multiple sclerosis; Pregnancy; Natalizumab; Intensive care medicine; Internal medicine; Immunology","score_opus":0.01914898633168949,"score_gpt":0.26108031739118004,"score_spread":0.24193133105949055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899137047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507433,0.0039812634,0.00033290198,0.000025027193,0.00008983302,0.0003743654,0.000005975364,0.0000062244253,0.00011007475],"genre_scores_gemma":[0.9990988,0.00035799545,0.0001890092,0.0002457524,0.00001853493,0.000065667344,0.000008771595,0.000012894227,0.0000026136438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987673,0.0001975428,0.00022092364,0.00031299255,0.0002861266,0.00021506856],"domain_scores_gemma":[0.99954706,0.000036642043,0.00008108892,0.00021567248,0.000096359116,0.00002318362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022839813,0.00014208435,0.00018640951,0.000053125652,0.000022326976,0.000004713698,0.00014418982,0.000088327666,0.000027085278],"category_scores_gemma":[0.00014609614,0.00010176302,0.000040703453,0.00013547903,0.00017011414,0.000015077169,0.00004360165,0.00007907138,9.843748e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005103975,0.00028213844,0.92950857,0.0000061718797,0.000011096693,1.16048e-7,0.00008763158,0.0007795783,0.001085825,0.000010088951,1.4163756e-7,0.06771825],"study_design_scores_gemma":[0.003422445,0.00097067707,0.9933516,0.000028354078,0.000023838651,5.025215e-8,0.00002002089,0.00034802523,0.0009063259,0.00068254024,0.000116792755,0.00012934451],"about_ca_topic_score_codex":0.0000052617734,"about_ca_topic_score_gemma":0.00022070583,"teacher_disagreement_score":0.06758891,"about_ca_system_score_codex":0.000004216274,"about_ca_system_score_gemma":0.000018818266,"threshold_uncertainty_score":0.41497755},"labels":[],"label_agreement":null},{"id":"W2922749437","doi":"10.1177/1756286419835708","title":"Outcome, efficacy and safety of endovascular thrombectomy in ischaemic stroke according to time to reperfusion: data from a multicentre registry","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"","keywords":"Medicine; Modified Rankin Scale; Confounding; Logistic regression; Stroke (engine); Odds ratio; Confidence interval; Internal medicine; Clinical trial; Surgery; Ischemic stroke; Ischemia","score_opus":0.021354438755035187,"score_gpt":0.3062179837653848,"score_spread":0.2848635450103496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922749437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901987,0.0023448165,0.0009426567,0.002364226,0.00008947346,0.0017462001,0.000038430513,0.000046555,0.0022289567],"genre_scores_gemma":[0.9928794,0.000885154,0.0029007776,0.0030120004,0.00002387401,0.000022736887,0.000038474285,0.000026101323,0.00021151837],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99773103,0.000110016685,0.00056413945,0.00088600925,0.00032520472,0.00038362376],"domain_scores_gemma":[0.9980487,0.0005510885,0.0001096301,0.0011592953,0.000016043086,0.00011520688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027252125,0.00025879339,0.00068675535,0.00014591396,0.000021070005,0.0000073950964,0.0005052353,0.00010467634,0.0003883794],"category_scores_gemma":[0.0003713846,0.00020833005,0.000058352227,0.00034906436,0.00009030199,0.00015145433,0.0008131717,0.00036925092,0.000086407024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045735524,0.00045120504,0.87051183,0.000098051816,0.00008893977,0.0000553347,0.00031675474,0.0015021142,0.02027951,0.000025123953,0.00007809992,0.102019496],"study_design_scores_gemma":[0.023847278,0.0021203386,0.77300435,0.00054993556,0.00030673578,0.000021057975,0.0018693134,0.012397949,0.00070258393,0.00018271523,0.18403663,0.00096110225],"about_ca_topic_score_codex":0.000047913367,"about_ca_topic_score_gemma":0.0000323692,"teacher_disagreement_score":0.18395853,"about_ca_system_score_codex":0.000028518914,"about_ca_system_score_gemma":0.000014585624,"threshold_uncertainty_score":0.8495453},"labels":[],"label_agreement":null},{"id":"W2944153925","doi":"10.1177/1756286419843458","title":"Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: A pilot study","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mirabegron; Overactive bladder; Urinary incontinence; Quality of life (healthcare); Urinary urgency; Parkinson's disease; Visual analogue scale; Refractory (planetary science); Montreal Cognitive Assessment; Urinary system; Rating scale; Urology; Physical therapy; Internal medicine; Disease; Cognitive impairment","score_opus":0.03204323492826271,"score_gpt":0.34293664964950843,"score_spread":0.3108934147212457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944153925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926524,0.0029314028,0.0000022020097,0.00028177106,0.00003132498,0.003785545,0.000022148377,0.000007997055,0.0002851799],"genre_scores_gemma":[0.99693316,0.002733329,0.0000042974375,0.00013451217,0.000003295631,0.00014998346,0.00001813299,0.000010585171,0.000012725569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977476,0.0008168928,0.00035153553,0.00039662822,0.0003885932,0.00029876127],"domain_scores_gemma":[0.9989092,0.00057513564,0.00008731869,0.00035249154,0.000029085752,0.000046781726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023059144,0.00018381175,0.00042984163,0.00010895176,0.0000142837835,0.0000033099902,0.00015638255,0.000034979275,0.00009073772],"category_scores_gemma":[0.000055133973,0.00010805863,0.000055854474,0.00042917984,0.0001591633,0.00009996991,0.000025246027,0.00023507379,0.000002345053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015996855,0.03952922,0.92888564,0.000047475474,0.000022325143,0.000010760435,0.0010354617,0.000080457045,0.0001265243,0.000007313465,0.0000010702375,0.014256915],"study_design_scores_gemma":[0.009035543,0.04569656,0.94331884,0.000013366589,0.00002219948,2.1022986e-7,0.00040683433,0.00013573327,0.000013248219,0.0009199797,0.00035399877,0.000083469284],"about_ca_topic_score_codex":0.0000947217,"about_ca_topic_score_gemma":0.00015066074,"teacher_disagreement_score":0.014433235,"about_ca_system_score_codex":0.000044127926,"about_ca_system_score_gemma":0.0000320091,"threshold_uncertainty_score":0.44065028},"labels":[],"label_agreement":null},{"id":"W2956892819","doi":"10.1177/1756286419860652","title":"Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Ultrasound and Hyperthermia Applications","field":"Engineering","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Randomized controlled trial; Odds ratio; Thrombolysis; Clinical trial; Clinical equipoise; Stroke (engine); Population; Post-hoc analysis; Internal medicine; Physical therapy; Myocardial infarction","score_opus":0.018548910621985673,"score_gpt":0.3288484960183792,"score_spread":0.3102995853963935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956892819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629304,0.0027526328,0.030540103,0.00015005747,0.00022513783,0.0024554261,0.000020620197,0.000085322084,0.0008403214],"genre_scores_gemma":[0.99027014,0.008325143,0.00046731622,0.00018024449,0.00003259861,0.0006718981,0.00001463319,0.000027112537,0.000010937277],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981936,0.00018552397,0.0008231748,0.00034013845,0.00013443593,0.0003231176],"domain_scores_gemma":[0.99768543,0.0018476393,0.00010295007,0.00030972285,0.000010873897,0.000043404507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064631656,0.00020838453,0.0010536314,0.00009609356,0.000018624334,0.000008587607,0.00028877103,0.00015620391,0.00008422337],"category_scores_gemma":[0.0000833013,0.00016608516,0.00042817558,0.00021122758,0.00020928172,0.00013044348,0.000022522072,0.0002933305,0.0000068556524],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6337051,0.0034345188,0.0027349198,0.0001357325,0.00089462195,0.0000035947608,0.00060006796,0.028676366,0.011436643,0.0053966558,0.000010091343,0.31297174],"study_design_scores_gemma":[0.9247955,0.00093192107,0.0002745751,0.000012618997,0.000251877,8.2047416e-7,0.00005308052,0.04456217,0.00017763229,0.016290532,0.012304461,0.0003447868],"about_ca_topic_score_codex":0.0000034249947,"about_ca_topic_score_gemma":0.000025545132,"teacher_disagreement_score":0.31262696,"about_ca_system_score_codex":0.00000807501,"about_ca_system_score_gemma":0.000013225457,"threshold_uncertainty_score":0.6772756},"labels":[],"label_agreement":null},{"id":"W3025164808","doi":"10.1177/1756286420915005","title":"Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Biogen","keywords":"Dimethyl fumarate; Medicine; Multiple sclerosis; Adverse effect; Expanded Disability Status Scale; Cohort; Placebo; Incidence (geometry); Internal medicine; Population; Relapsing remitting; Magnetic resonance imaging; Gastroenterology; Pathology; Radiology; Immunology","score_opus":0.031607016600169534,"score_gpt":0.272147108999602,"score_spread":0.24054009239943244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025164808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362415,0.0048944997,0.00014981983,0.00039523354,0.000024789777,0.0007830209,0.00001819006,0.00002184933,0.00008846711],"genre_scores_gemma":[0.9903754,0.008714699,0.00045505163,0.00040117977,0.0000062109357,0.00001804024,0.0000073870056,0.00001993792,0.00000207829],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99828565,0.000167859,0.00048199497,0.00043203865,0.00030857854,0.00032385465],"domain_scores_gemma":[0.9984852,0.001009917,0.0001679877,0.00016101917,0.000054094286,0.000121749144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019157588,0.00020558314,0.00060272054,0.00009586117,0.000039318777,0.000004865157,0.00010390179,0.00007670588,0.000013360223],"category_scores_gemma":[0.0010034605,0.00015268156,0.000047997375,0.00038128527,0.00060528907,0.000107327316,0.00012755887,0.00035712396,6.0635995e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013656095,0.00036799448,0.8594969,0.00010706603,0.00004626116,0.000003136296,0.0007012793,0.0004691826,0.0009835965,0.000036100686,9.004366e-7,0.1241315],"study_design_scores_gemma":[0.018542644,0.002616868,0.97596115,0.00013340192,0.000036772544,3.546013e-7,0.0001610112,0.0021153532,0.00007218437,0.00008782133,0.00013980673,0.00013261738],"about_ca_topic_score_codex":0.000051110143,"about_ca_topic_score_gemma":0.000101715304,"teacher_disagreement_score":0.12399889,"about_ca_system_score_codex":0.000008730706,"about_ca_system_score_gemma":0.000019579691,"threshold_uncertainty_score":0.62261736},"labels":[],"label_agreement":null},{"id":"W3034546965","doi":"10.1177/1756286420932036","title":"Neurological manifestations and implications of COVID-19 pandemic","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":148,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Pandemic; Comorbidity; Neurology; Intensive care medicine; Stroke (engine); Coronavirus; Disease; Hyposmia; Pediatrics; Encephalopathy; Coronavirus disease 2019 (COVID-19); Internal medicine; Psychiatry; Infectious disease (medical specialty)","score_opus":0.06617230146732682,"score_gpt":0.4122730557635806,"score_spread":0.34610075429625375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034546965","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00051704585,0.9865526,0.001602311,0.0077777547,0.00008993558,0.0027400993,0.000065260596,0.0002167749,0.00043820214],"genre_scores_gemma":[0.006779153,0.981192,0.0003176806,0.011075399,0.00004766828,0.00043860925,0.000081429076,0.00005657492,0.000011465947],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965355,0.0007717967,0.0009370674,0.0010126081,0.0002788451,0.00046421247],"domain_scores_gemma":[0.9929162,0.005572705,0.00046200372,0.0005540356,0.000028328572,0.00046669462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027241767,0.0005842949,0.0020100465,0.00026323795,0.00010013945,0.000015724363,0.00047135138,0.0004626103,0.00009890104],"category_scores_gemma":[0.0018636396,0.0004166366,0.0003825424,0.0006891616,0.0008511738,0.00011831055,0.00020811075,0.0011306322,0.000014862216],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002315719,0.00026900732,0.024555951,0.008782916,0.000062426174,0.00013453506,0.000056854395,0.00004515886,0.0000015312163,0.003234155,0.000015331452,0.96261054],"study_design_scores_gemma":[0.0010737483,0.0016343541,0.009326547,0.00029806994,0.0006841277,0.0004891612,0.000009674733,0.00008589395,1.6748324e-8,0.02498902,0.96105814,0.00035125052],"about_ca_topic_score_codex":0.000005668077,"about_ca_topic_score_gemma":0.000026123114,"teacher_disagreement_score":0.9622593,"about_ca_system_score_codex":0.000046074663,"about_ca_system_score_gemma":0.0003651522,"threshold_uncertainty_score":0.9998285},"labels":[],"label_agreement":null},{"id":"W3037795043","doi":"10.1177/1756286420935019","title":"Expert opinion on the use of cladribine tablets in clinical practice","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Expert opinion; Cladribine; Clinical Practice; Alternative medicine; Intensive care medicine; Traditional medicine; Medical physics; Family medicine; Internal medicine; Pathology","score_opus":0.3616787011441253,"score_gpt":0.5036940022402069,"score_spread":0.14201530109608157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037795043","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028151642,0.98740506,0.000056058638,0.009152743,0.00027012423,0.0024681878,0.000013662586,0.000036852274,0.0005691389],"genre_scores_gemma":[0.00038024053,0.99241984,0.0003626467,0.006285862,0.00012270117,0.00035485017,0.000017926537,0.000047595466,0.0000083358145],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99410146,0.0024550208,0.0014600442,0.0008203675,0.00065227493,0.0005108328],"domain_scores_gemma":[0.9822064,0.01649014,0.0004995503,0.0006334197,0.000059324862,0.00011118274],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008569019,0.0004893453,0.0023306194,0.00016835397,0.000048882153,0.000016141805,0.00046941458,0.00034310986,0.00007588428],"category_scores_gemma":[0.011317494,0.00025791855,0.00046319704,0.0008519713,0.0007151378,0.00018202123,0.00027446487,0.0022926545,0.000024034212],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009168642,0.00088381284,0.00032553414,0.00082298886,0.00008589098,0.000035734924,0.00005057941,0.000032344356,3.9032753e-7,0.000343305,0.00015195704,0.9963506],"study_design_scores_gemma":[0.00089770585,0.0018175463,0.0014564084,0.0020977815,0.000045674566,0.0000069046655,0.00003949203,0.00025416023,7.939823e-8,0.00014040813,0.9930471,0.00019671777],"about_ca_topic_score_codex":0.000014155175,"about_ca_topic_score_gemma":0.00001820621,"teacher_disagreement_score":0.9961539,"about_ca_system_score_codex":0.00004156855,"about_ca_system_score_gemma":0.000121611134,"threshold_uncertainty_score":0.9999873},"labels":[],"label_agreement":null},{"id":"W3046496809","doi":"10.1177/1756286420936165","title":"Multiple sclerosis and nutrition: back to the future?","year":2020,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Deutschen Multiple Sklerose Gesellschaft; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Multiple sclerosis; Clinical neurology; Physical medicine and rehabilitation; Intensive care medicine; Neuroscience; Immunology","score_opus":0.03862480676914403,"score_gpt":0.31613213964389814,"score_spread":0.2775073328747541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046496809","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004791184,0.20730971,0.00047817326,0.21220146,0.56097066,0.010984883,0.0005106956,0.00039945514,0.0023537613],"genre_scores_gemma":[0.049122974,0.50399745,0.00077004783,0.008891351,0.43551788,0.0013110157,0.00014262438,0.0001217051,0.00012497751],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966846,0.00033569962,0.00043977823,0.0009707715,0.0009291221,0.0006400315],"domain_scores_gemma":[0.99656487,0.0025161584,0.00010378878,0.00046400502,0.00009920247,0.0002519982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024874165,0.0004920461,0.0008408932,0.000115709525,0.00018949895,0.000052770774,0.00047741135,0.00044144018,0.000121486875],"category_scores_gemma":[0.0013949667,0.00030234133,0.00016290757,0.000550261,0.00050569756,0.00010404803,0.00039531285,0.0018062154,0.00009581488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006197892,0.0007204029,0.005771733,0.000792976,0.00013307286,0.000024900673,0.0004238069,0.00005247191,0.0000938806,0.000042677577,0.59843475,0.38731143],"study_design_scores_gemma":[0.0027030655,0.0017201678,0.01592174,0.0001377038,0.000045086,0.0000011007185,0.00016959499,0.00019739555,0.0000028149573,0.0004226668,0.97839904,0.0002796221],"about_ca_topic_score_codex":0.000009902281,"about_ca_topic_score_gemma":0.00037961357,"teacher_disagreement_score":0.3870318,"about_ca_system_score_codex":0.000033306773,"about_ca_system_score_gemma":0.000053677926,"threshold_uncertainty_score":0.9999429},"labels":[],"label_agreement":null},{"id":"W3089064542","doi":"10.1177/1756286420954083","title":"Standardized algorithm for muscle selection and dosing of botulinum toxin for Parkinson tremor using kinematic analysis","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Neurological disorders and treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Lawson Health Research Institute; Western University","funders":"Merz Pharmaceuticals","keywords":"Medicine; Dosing; Botulinum toxin; Rating scale; Physical medicine and rehabilitation; Essential tremor; Quality of life (healthcare); Grip strength; Weakness; Physical therapy; Anesthesia; Internal medicine; Psychology; Surgery","score_opus":0.03389466039749872,"score_gpt":0.3268518546039901,"score_spread":0.29295719420649136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089064542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6528541,0.0025326842,0.34134686,0.0016643845,0.000035964633,0.0014445123,0.000040660583,0.000048520185,0.00003231882],"genre_scores_gemma":[0.96824485,0.0009800959,0.027839558,0.0027783832,0.000023495011,0.0000946402,0.000015821488,0.000020330217,0.0000028171767],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9985971,0.00009342827,0.00038588422,0.00047459596,0.00015342586,0.00029559157],"domain_scores_gemma":[0.9992094,0.00040759792,0.00015248476,0.000097167285,0.000041953812,0.00009140414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001221303,0.00020928208,0.0006866121,0.00010475714,0.00007774639,0.000010661734,0.00006660178,0.000095334144,0.000022218825],"category_scores_gemma":[0.00012974042,0.0001546173,0.00023511809,0.00057413476,0.00011657217,0.000088175926,0.000022003373,0.00012121159,1.4625633e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060527376,0.001055953,0.04615466,0.00039824328,0.00051604887,0.00000880003,0.00024112989,0.009106105,0.0037914217,0.00025520558,0.000005044139,0.93241465],"study_design_scores_gemma":[0.011589636,0.006893857,0.031720255,0.0000219883,0.0017224408,0.0000019398437,0.000118673735,0.90848196,0.00026138438,0.036574945,0.0023231332,0.00028978084],"about_ca_topic_score_codex":0.000004778446,"about_ca_topic_score_gemma":0.000015511941,"teacher_disagreement_score":0.93212485,"about_ca_system_score_codex":0.0000102600325,"about_ca_system_score_gemma":0.000015362966,"threshold_uncertainty_score":0.63051105},"labels":[],"label_agreement":null},{"id":"W3111513828","doi":"10.1177/1756286420978004","title":"COVID-19 and cerebrovascular diseases: a comprehensive overview","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Long-Term Effects of COVID-19","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Stroke (engine); Intracerebral hemorrhage; Disease; Intensive care medicine; Coagulopathy; Internal medicine; Subarachnoid hemorrhage","score_opus":0.05047681182604093,"score_gpt":0.38743677680631444,"score_spread":0.33695996498027353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111513828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035437504,0.99054945,0.00040818687,0.004086957,0.00019173698,0.0042262636,0.000057246983,0.00028417833,0.00016052782],"genre_scores_gemma":[0.0002594889,0.96006835,0.00013600358,0.03874511,0.00010561658,0.00045541459,0.00010960062,0.0001081618,0.000012281894],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99527717,0.0011744841,0.0008393718,0.0014882651,0.0005427934,0.00067793904],"domain_scores_gemma":[0.99387896,0.0038114267,0.00036175226,0.0007816607,0.000028755905,0.0011374315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015411558,0.0010039611,0.0036602176,0.00025478296,0.00011930219,0.00004176742,0.00053269137,0.00045706503,0.00023962776],"category_scores_gemma":[0.0015184637,0.0007096633,0.0008864491,0.00077016937,0.00077728526,0.00018033416,0.0003643213,0.001209432,0.00005392125],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023916722,0.00026398795,0.0016263041,0.064296745,0.0002460341,0.00037463414,0.000051920484,0.000029798714,9.915785e-8,0.00090098707,0.000044639946,0.9319257],"study_design_scores_gemma":[0.0021979874,0.0011292202,0.0008067793,0.0019179439,0.0017066277,0.00017065331,0.000015963675,0.00008550371,9.173566e-9,0.0070904805,0.9842591,0.0006196781],"about_ca_topic_score_codex":0.000011560919,"about_ca_topic_score_gemma":0.000012908698,"teacher_disagreement_score":0.9842145,"about_ca_system_score_codex":0.00012872668,"about_ca_system_score_gemma":0.0006158173,"threshold_uncertainty_score":0.99953544},"labels":[],"label_agreement":null},{"id":"W3125508314","doi":"10.1177/1756286420986727","title":"Real-world comparative safety and efficacy of tenecteplase <i>versus</i> alteplase in acute ischemic stroke patients with large vessel occlusion","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Tenecteplase; Medicine; Thrombolysis; Modified Rankin Scale; Stroke (engine); Fibrinolytic agent; Occlusion; Tissue plasminogen activator; Internal medicine; Anesthesia; Ischemia; Ischemic stroke; Myocardial infarction","score_opus":0.011863109917511558,"score_gpt":0.2901336311178049,"score_spread":0.27827052120029333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125508314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98809147,0.0009936354,0.0003179332,0.00057119195,0.00007800255,0.00067226135,0.00005213598,0.00003695461,0.009186394],"genre_scores_gemma":[0.992275,0.0057720477,0.0007239246,0.0009713647,0.000009154865,0.000018910858,0.00009584875,0.00001990428,0.00011382996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981179,0.00013618745,0.0004377488,0.00057241536,0.0003300784,0.00040567032],"domain_scores_gemma":[0.9987902,0.0005831673,0.00016393478,0.00031920162,0.00005342573,0.00009007121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011245847,0.00028054276,0.0006208483,0.00014419717,0.00004689546,0.0000060148336,0.00013201773,0.00007735884,0.0000595325],"category_scores_gemma":[0.000060071176,0.0002107786,0.000057602352,0.0005628578,0.00025501882,0.0001454817,0.00020606778,0.00041191172,0.000002012427],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03946665,0.0030742332,0.94111764,0.0001235873,0.0002227281,0.00022836597,0.0005075254,0.000690326,0.0018801092,0.00042557702,0.0001900018,0.012073235],"study_design_scores_gemma":[0.040223252,0.002375288,0.9160654,0.00013780361,0.0002661469,0.000006486077,0.00037540225,0.0013529413,0.001318463,0.000068904854,0.037416123,0.00039376598],"about_ca_topic_score_codex":0.00000937044,"about_ca_topic_score_gemma":0.00023507577,"teacher_disagreement_score":0.037226122,"about_ca_system_score_codex":0.000036046953,"about_ca_system_score_gemma":0.00003577432,"threshold_uncertainty_score":0.8595302},"labels":[],"label_agreement":null},{"id":"W3135190823","doi":"10.1177/1756286420987941","title":"Safety and efficacy of daclizumab beta in patients with relapsing multiple sclerosis in a 5-year open-label study (EXTEND): final results following early termination","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"AbbVie Biotherapeutics; Biogen","keywords":"Medicine; Daclizumab; Multiple sclerosis; BETA (programming language); Relapsing remitting; Internal medicine; Oncology; Immunology; Monoclonal antibody; Antibody","score_opus":0.06762489834413932,"score_gpt":0.341432496039235,"score_spread":0.27380759769509566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3135190823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99649715,0.0009578342,0.000029063654,0.00044169484,0.000041349667,0.0017242808,0.0000118752805,0.000015753574,0.00028100188],"genre_scores_gemma":[0.99742687,0.0017730808,0.00058305706,0.00010357759,0.000004961255,0.000061020495,0.000017137689,0.000020143963,0.000010148828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732745,0.00049283326,0.00062894396,0.0006707203,0.0004739474,0.00040613665],"domain_scores_gemma":[0.9983788,0.0010513141,0.00013436624,0.0003087583,0.00006472931,0.000062030944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051322277,0.00022263132,0.0006221178,0.00019923436,0.000080146434,0.000026691163,0.00020728409,0.00007653339,0.000004990526],"category_scores_gemma":[0.001087745,0.00017106134,0.00003508268,0.0007863368,0.00021255712,0.00033785918,0.0003138225,0.0004634106,5.6660576e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014774251,0.004958198,0.8391606,0.000027743376,0.000029989777,0.000032979027,0.00092957244,0.00015833632,0.00012204666,0.000011873842,2.316247e-7,0.13979417],"study_design_scores_gemma":[0.066970475,0.0036248958,0.92770153,0.0002797577,0.000024610186,4.3130876e-7,0.0004721851,0.00063669455,0.000011789554,0.00009434193,0.00003575837,0.00014751121],"about_ca_topic_score_codex":0.000087017484,"about_ca_topic_score_gemma":0.0011928086,"teacher_disagreement_score":0.13964665,"about_ca_system_score_codex":0.000045887322,"about_ca_system_score_gemma":0.00004076344,"threshold_uncertainty_score":0.6975679},"labels":[],"label_agreement":null},{"id":"W3138369521","doi":"10.1177/1756286421998905","title":"Expanding indications for endovascular thrombectomy-how to leave no patient behind","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Thrombolysis; Stroke (engine); Occlusion; Endovascular treatment; Standard of care; Radiology; Intensive care medicine; Surgery; Myocardial infarction; Cardiology","score_opus":0.041407256598224786,"score_gpt":0.35767947750906637,"score_spread":0.31627222091084156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138369521","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000071325754,0.9831096,0.008471159,0.0010147995,0.00039826625,0.004631452,0.00003601615,0.00009107905,0.0021763036],"genre_scores_gemma":[0.00049566466,0.9911317,0.0030107717,0.002299587,0.00013324819,0.0024291978,0.00019841029,0.00008871035,0.0002127134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970354,0.00021142897,0.0006419852,0.0010630114,0.00040832203,0.0006398892],"domain_scores_gemma":[0.9980146,0.0007564317,0.00029268375,0.00071914797,0.000059474016,0.00015763762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018929981,0.0005914287,0.0019187919,0.00029833376,0.000096907075,0.000034626526,0.0003907183,0.00029868222,0.00014378763],"category_scores_gemma":[0.0004694115,0.0004468702,0.0007381348,0.0004832975,0.00014825605,0.00009616777,0.0002623081,0.00064627535,0.000039221595],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005074174,0.0002830859,0.00007712863,0.002103079,0.000243857,0.000028380458,0.00010908874,0.000016165654,0.000001963704,0.00017353844,0.00043013092,0.99648285],"study_design_scores_gemma":[0.00074127404,0.00091286405,0.000029216037,0.0015046506,0.0008294358,0.000019463829,0.000093160204,0.000019825953,0.000002229234,0.0001942514,0.9952685,0.00038508078],"about_ca_topic_score_codex":0.000001414835,"about_ca_topic_score_gemma":0.0000072030384,"teacher_disagreement_score":0.99609774,"about_ca_system_score_codex":0.00009874735,"about_ca_system_score_gemma":0.00008865623,"threshold_uncertainty_score":0.9997983},"labels":[],"label_agreement":null},{"id":"W3157239883","doi":"10.1177/1756286420982134","title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"NIHR Cambridge Biomedical Research Centre; Bayer HealthCare; National Institute for Health and Care Research; Sanofi","keywords":"Alemtuzumab; Medicine; Multiple sclerosis; Internal medicine; Clinical trial; Randomized controlled trial; Immunology; Transplantation","score_opus":0.04590724287686678,"score_gpt":0.3464066050044256,"score_spread":0.30049936212755884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157239883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98957354,0.007630331,0.00001921241,0.00092845794,0.000117169,0.00069601,0.000018620574,0.000012270373,0.0010044],"genre_scores_gemma":[0.9827612,0.016765554,0.00013808682,0.00025660047,0.000028046463,0.0000128590955,0.0000046421223,0.0000092523505,0.00002377042],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99837816,0.00028041922,0.0003933063,0.00033481352,0.00038833747,0.0002249613],"domain_scores_gemma":[0.9986596,0.0007631966,0.0001134872,0.0003515774,0.00007171384,0.000040432078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018687802,0.00012526037,0.00038596473,0.000042259628,0.00004151692,0.0000034895813,0.00012659868,0.00007542332,0.000041119558],"category_scores_gemma":[0.0011262167,0.000077893914,0.0001000902,0.00028642913,0.0005803653,0.000045828183,0.0001925204,0.00029580554,6.842783e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34772274,0.001760983,0.05559482,0.0003122738,0.00012713265,0.000036786343,0.0020083014,0.00097358756,0.009869599,0.0006082974,0.000053266875,0.5809322],"study_design_scores_gemma":[0.06013605,0.0017191009,0.92896146,0.0000857799,0.000033259035,0.0000025311222,0.00024767802,0.00013786957,0.00031211213,0.00058160425,0.007699183,0.00008336526],"about_ca_topic_score_codex":0.000013025871,"about_ca_topic_score_gemma":0.00005952339,"teacher_disagreement_score":0.87336665,"about_ca_system_score_codex":0.000011429852,"about_ca_system_score_gemma":0.000049521463,"threshold_uncertainty_score":0.31764215},"labels":[],"label_agreement":null},{"id":"W3162974988","doi":"10.1177/17562864211014389","title":"A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Neuromyelitis optica; Medicine; Disease; Subclinical infection; Spectrum disorder; Magnetic resonance imaging; Multiple sclerosis; Intensive care medicine; Pediatrics; Pathology; Immunology; Radiology; Psychiatry","score_opus":0.06666058728059476,"score_gpt":0.4407415941948044,"score_spread":0.37408100691420965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162974988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019555652,0.9728961,0.00043729861,0.018396301,0.00043910978,0.007338955,0.000060202052,0.00003928575,0.00019716201],"genre_scores_gemma":[0.006677089,0.988718,0.00009380861,0.0008421107,0.00035697295,0.0031243404,0.00008765596,0.00007585783,0.000024220168],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99420285,0.001960304,0.00090183545,0.00092314556,0.0013132532,0.0006986353],"domain_scores_gemma":[0.9946333,0.0034629074,0.00040319256,0.0011533024,0.00021652458,0.00013077103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001399362,0.0006509735,0.0018582841,0.00009861183,0.00030043672,0.00003821253,0.00078108395,0.00019968803,0.00013229605],"category_scores_gemma":[0.0012854015,0.00030029664,0.00093900604,0.0007924485,0.0013121101,0.00011542566,0.0002937158,0.0010093582,0.000005212693],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026983296,0.0004561079,0.0005788694,0.0023411887,0.00023630231,0.0000059715044,0.00020762045,0.00032371984,2.0638147e-7,0.0010568668,0.00002894193,0.9944944],"study_design_scores_gemma":[0.002106015,0.0006309576,0.009930923,0.0010466418,0.0024082263,0.000007097641,0.00040127686,0.0016668804,1.3454103e-7,0.007893695,0.97358495,0.00032321987],"about_ca_topic_score_codex":0.0000098458995,"about_ca_topic_score_gemma":0.00021082189,"teacher_disagreement_score":0.99417114,"about_ca_system_score_codex":0.000059532023,"about_ca_system_score_gemma":0.0005056835,"threshold_uncertainty_score":0.9999449},"labels":[],"label_agreement":null},{"id":"W3164111830","doi":"10.1177/17562864211018561","title":"Cannabis and its derivatives for the use of motor symptoms in Parkinson’s disease: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Cannabis and Cannabinoid Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Meta-analysis; Parkinson's disease; Motor symptoms; Disease; Cannabis; Systematic review; Psychiatry; Neuroscience; MEDLINE; Physical medicine and rehabilitation; Intensive care medicine; Internal medicine; Psychology","score_opus":0.11506435694121224,"score_gpt":0.3927733063084333,"score_spread":0.27770894936722107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164111830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000024373334,0.98696125,0.000072514675,0.005443896,0.00001464631,0.0073116324,0.00015883442,0.0000101973965,0.0000026377766],"genre_scores_gemma":[0.00032815995,0.9917637,0.000020723768,0.0016711002,0.000006189514,0.0057108575,0.000026412654,0.000032685904,0.00044015507],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965674,0.0009873649,0.0010267297,0.00070580945,0.00034059133,0.00037208368],"domain_scores_gemma":[0.99793386,0.00091551297,0.00039148048,0.00052834797,0.00009503637,0.00013574013],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055782165,0.00046336083,0.005915118,0.00027628455,0.000054117507,0.00003072419,0.000240265,0.00013858745,0.000074163094],"category_scores_gemma":[0.001108742,0.00022776103,0.0013014181,0.0011763957,0.0003258378,0.000103202445,0.0001311149,0.00043246947,2.292933e-7],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012099489,0.00025458448,0.00013983766,0.917254,0.021552764,0.000024846784,0.00004798751,0.000030447518,1.0101562e-7,0.00041984647,0.000042354703,0.060112268],"study_design_scores_gemma":[0.0003184997,0.00030955323,0.00058160524,0.008516315,0.3697806,0.000010434127,0.000019302717,0.00034973602,2.5020075e-8,0.000103170125,0.61974686,0.00026390312],"about_ca_topic_score_codex":0.00001007198,"about_ca_topic_score_gemma":0.00008663099,"teacher_disagreement_score":0.90873766,"about_ca_system_score_codex":0.000022111466,"about_ca_system_score_gemma":0.00011956691,"threshold_uncertainty_score":0.9287825},"labels":[],"label_agreement":null},{"id":"W3173363521","doi":"10.1177/17562864211021177","title":"A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Biogen","keywords":"Fingolimod; Medicine; Dimethyl fumarate; Propensity score matching; Internal medicine; Hazard ratio; Confidence interval; Multiple sclerosis; Relapsing remitting; Gastroenterology; Disease; Immunology","score_opus":0.08033330319553018,"score_gpt":0.33582630447555095,"score_spread":0.2554930012800208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173363521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99708897,0.0008264144,0.00017468989,0.00037919797,0.000018132248,0.0013729053,0.000009390548,0.00005049358,0.00007981097],"genre_scores_gemma":[0.9981864,0.000898389,0.0005188552,0.00017425024,0.000006707501,0.00014099992,0.000031658325,0.000029771449,0.000012966006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971876,0.00046745254,0.00054001797,0.0006999147,0.0005372468,0.00056776585],"domain_scores_gemma":[0.9982849,0.0008460922,0.00017679078,0.00043785473,0.00014889553,0.0001054757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018997768,0.00033289022,0.0010698346,0.0000892145,0.00008084012,0.000016160886,0.000168931,0.00009863885,0.00007140428],"category_scores_gemma":[0.00043533862,0.00018984526,0.00006940302,0.0009996986,0.0008881738,0.00019054163,0.00014574111,0.0005384084,0.000001729713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01596845,0.003497645,0.9070178,0.00017358888,0.00006762551,0.000022927403,0.00033916163,0.0011845527,0.00043646563,0.0000020556988,2.7972246e-7,0.07128945],"study_design_scores_gemma":[0.009506776,0.0030992848,0.98495305,0.00026923558,0.00004459764,0.0000011142079,0.00018401172,0.0010912422,0.00059505354,0.00001882242,0.000017520339,0.00021930171],"about_ca_topic_score_codex":0.000045015277,"about_ca_topic_score_gemma":0.0030496707,"teacher_disagreement_score":0.07793524,"about_ca_system_score_codex":0.000052203763,"about_ca_system_score_gemma":0.00004999725,"threshold_uncertainty_score":0.7741665},"labels":[],"label_agreement":null},{"id":"W4226062860","doi":"10.1177/17562864211058298","title":"Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"EMD Serono; MedDay Pharmaceuticals; Genentech; Serono Symposia International Foundation; Servier; Aristotle University of Thessaloniki; Pirogov Russian National Research Medical University; Medizinische Universität Wien; Rigshospitalet; Università degli Studi di Genova; Hebrew University of Jerusalem; Universität Wien; Queen Mary University of London; CSL Behring; Gentofte Hospital; Fresenius Medical Care North America; Five Prime Therapeutics; Ironwood Pharmaceuticals, Incorporated; Vertex Pharmaceuticals; Ottawa Hospital Research Institute; Bayer Vital; Bristol-Myers Squibb; Bundesministerium für Bildung und Forschung; Atara Biotherapeutics; Merck KGaA; Univerzita Karlova v Praze; Pfizer; Biogen; Celgene; Teva Pharmaceutical Industries; Sanofi; GW Pharmaceuticals; Università degli Studi di Napoli Federico II; Bayer HealthCare; Deutsche Forschungsgemeinschaft; Directorate for Biological Sciences; GlaxoSmithKline","keywords":"Cladribine; Medicine; Expert opinion; Vaccination; Coronavirus disease 2019 (COVID-19); Clinical Practice; Dosing; MEDLINE; Multiple sclerosis; Family medicine; Intensive care medicine; Pharmacology; Internal medicine; Pathology; Immunology; Disease; Infectious disease (medical specialty)","score_opus":0.31871533135323626,"score_gpt":0.5275843612080184,"score_spread":0.20886902985478217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226062860","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003834007,0.9894888,0.0002038169,0.00756501,0.00020180948,0.0022614307,0.000008868833,0.000022324732,0.0002096346],"genre_scores_gemma":[0.00049661775,0.9920327,0.00032577803,0.0066604493,0.00006421012,0.0003474217,0.000034328154,0.000027910432,0.000010582134],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935616,0.0036290374,0.0012106989,0.00072985364,0.00050882855,0.00035994645],"domain_scores_gemma":[0.9763496,0.022499029,0.00047010102,0.00048785406,0.00007448727,0.000118924094],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0016100553,0.0003693174,0.0020928907,0.00020461618,0.00006574774,0.000021265649,0.00022755074,0.00031114457,0.000056233643],"category_scores_gemma":[0.022795117,0.00020177777,0.00028892103,0.00063970475,0.000613494,0.00019307414,0.00023072363,0.001357626,0.0000021489814],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015163589,0.0006803052,0.00048694105,0.0013654609,0.00007463028,0.000021972204,0.00009076264,0.000087546665,9.413724e-8,0.00081723096,0.000065836546,0.9947929],"study_design_scores_gemma":[0.0038830598,0.00080111035,0.0024178703,0.0011618015,0.00006222111,0.000015923248,0.000068783076,0.00036581067,2.7666294e-8,0.00026193145,0.99080247,0.00015899466],"about_ca_topic_score_codex":0.00003448931,"about_ca_topic_score_gemma":0.00005575205,"teacher_disagreement_score":0.99463385,"about_ca_system_score_codex":0.00005933724,"about_ca_system_score_gemma":0.00017532437,"threshold_uncertainty_score":0.9854363},"labels":[],"label_agreement":null},{"id":"W4285250308","doi":"10.1177/17562864221099472","title":"Effects of low molecular weight heparin and fondaparinux on mortality, hemorrhagic and thrombotic complications in COVID-19 patients","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Fondaparinux; Low molecular weight heparin; Internal medicine; Cochrane Library; Thrombosis; Randomized controlled trial; Meta-analysis; Dosing; Cohort study; Observational study; Venous thromboembolism","score_opus":0.024988881798681674,"score_gpt":0.3877964226678904,"score_spread":0.3628075408692087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285250308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901476,0.0034799306,0.00032639492,0.0045712707,0.000039985593,0.0011952448,0.0000061569162,0.000027616092,0.00020579521],"genre_scores_gemma":[0.98386204,0.004839955,0.00004598023,0.010966754,0.0000033285614,0.00025718432,0.0000075486573,0.000012880371,0.000004341977],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979843,0.0004096146,0.00036233905,0.0005231954,0.0004097283,0.00031085633],"domain_scores_gemma":[0.9947998,0.0046904227,0.000090354864,0.00025178114,0.000019265295,0.00014838592],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002720324,0.00018027522,0.00047132093,0.00015186256,0.000103453975,0.0000057238485,0.00016597033,0.000048638463,0.000024237219],"category_scores_gemma":[0.0027635556,0.00014746137,0.00005476445,0.00040323468,0.0006164423,0.000054822754,0.00038642748,0.0005162497,9.1890126e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087670394,0.0023254836,0.96223575,0.00074456085,0.000034928016,0.000057680452,0.00017255395,0.0038491585,0.00024677615,0.0020799756,0.000003411596,0.027372994],"study_design_scores_gemma":[0.0041914075,0.0025782601,0.94327843,0.0000242834,0.00003301369,9.4572647e-7,0.000025530922,0.0028567219,0.000021181682,0.046037253,0.000818566,0.00013437761],"about_ca_topic_score_codex":0.000035270197,"about_ca_topic_score_gemma":0.00003660229,"teacher_disagreement_score":0.043957278,"about_ca_system_score_codex":0.00005270264,"about_ca_system_score_gemma":0.000050978677,"threshold_uncertainty_score":0.60133004},"labels":[],"label_agreement":null},{"id":"W4310782882","doi":"10.1177/17562864221139632","title":"Endovascular treatment for anterior circulation large-vessel occlusion ischemic stroke with low ASPECTS: a systematic review and meta-analysis","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Modified Rankin Scale; Stroke (engine); MEDLINE; Systematic review; Ischemic stroke; Randomized controlled trial; Internal medicine; Clinical trial; Ischemia","score_opus":0.04180377092369003,"score_gpt":0.3360274067380769,"score_spread":0.2942236358143869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310782882","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015933516,0.9837311,0.0038364658,0.0003176756,0.00002496097,0.011533639,0.00012638418,0.00007555828,0.00033831206],"genre_scores_gemma":[0.00045061935,0.99083114,0.00031493965,0.0019920783,0.000011862175,0.0059175338,0.00027235394,0.000072283874,0.0001371912],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961688,0.0005341132,0.0011475858,0.0011556566,0.0004951729,0.0004986957],"domain_scores_gemma":[0.99746794,0.0007230032,0.000790373,0.0008931282,0.000029423782,0.000096134434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005269094,0.00083698763,0.007915465,0.0003721829,0.00012212909,0.000021476275,0.00029576605,0.00015905121,0.00036399422],"category_scores_gemma":[0.00011836735,0.00046415595,0.0024189386,0.00090014905,0.00011035835,0.000104899154,0.00016178555,0.00038452513,0.0000024802919],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018988791,0.00082780793,0.000042310556,0.8123308,0.13856818,0.00012403342,0.00007029613,0.00006997013,8.2319065e-7,0.00005577681,0.0000142275385,0.04770592],"study_design_scores_gemma":[0.0010466346,0.0008000045,0.0000051139245,0.003887072,0.6197812,0.00006833652,0.000035703728,0.00016472297,1.2077606e-7,0.000018170738,0.37384844,0.00034449666],"about_ca_topic_score_codex":0.0000026721282,"about_ca_topic_score_gemma":0.000012563844,"teacher_disagreement_score":0.8084437,"about_ca_system_score_codex":0.00014064126,"about_ca_system_score_gemma":0.000055876942,"threshold_uncertainty_score":0.999781},"labels":[],"label_agreement":null},{"id":"W4318815070","doi":"10.1177/17562864221150329","title":"Plasma extracellular vesicle tau, β-amyloid, and α-synuclein and the progression of Parkinson’s disease: a follow-up study","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Taipei Medical University-Shuang Ho Hospital, Ministry of Health and Welfare; Taipei Medical University; Parkinsonfonden; National Taiwan University; National Taiwan University Hospital; Ministry of Science and Technology, Taiwan","keywords":"Medicine; Parkinson's disease; Internal medicine; Biomarker; Disease; Cohort; Alpha-synuclein; Oncology; Endocrinology; Biology","score_opus":0.01881479634039804,"score_gpt":0.29505705972939855,"score_spread":0.2762422633890005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318815070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98006386,0.017111884,0.000034943576,0.0011546043,0.00008381877,0.0013700078,0.000008293012,0.000076208446,0.000096381016],"genre_scores_gemma":[0.99134487,0.00805897,0.000046377627,0.0002109136,0.000011369182,0.00023932615,0.00000568143,0.000021271579,0.000061192426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984263,0.00025711526,0.00026524795,0.0004591516,0.00029535405,0.00029683526],"domain_scores_gemma":[0.9991954,0.0002990129,0.00009592835,0.0002563165,0.0000147063465,0.00013863668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027850267,0.00021364578,0.00038239348,0.000084631705,0.00011254178,0.000014534809,0.00010823489,0.00005207755,0.000024145962],"category_scores_gemma":[0.000083685045,0.00012274084,0.00007341932,0.00031776965,0.00040347103,0.000091056034,0.000104855535,0.00016380014,0.000004555273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011625517,0.0014886688,0.61157185,0.000096730924,0.000103028004,0.00024381978,0.000641637,0.000051422077,0.00025741706,0.0019786453,0.0000051424304,0.3719361],"study_design_scores_gemma":[0.016728463,0.0019778162,0.9459079,0.00004575602,0.00026093403,0.0000062790095,0.0007260434,0.0066561266,0.000032354208,0.014945077,0.0125384275,0.00017484988],"about_ca_topic_score_codex":0.0000065370623,"about_ca_topic_score_gemma":0.000019098194,"teacher_disagreement_score":0.37176126,"about_ca_system_score_codex":0.000005324441,"about_ca_system_score_gemma":0.000016634369,"threshold_uncertainty_score":0.5005226},"labels":[],"label_agreement":null},{"id":"W4380785062","doi":"10.1177/17562864231180715","title":"Arterial stiffness and its influence on cerebral morphology and cognitive function","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Cardiovascular Health and Disease Prevention","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Alzheimer Society","keywords":"Arterial stiffness; Medicine; Pulse wave velocity; Cardiology; Hyperintensity; Internal medicine; Blood pressure; Dementia; Ambulatory blood pressure; Pulse pressure; Magnetic resonance imaging; Disease; Radiology","score_opus":0.017981206129568533,"score_gpt":0.3056240441426175,"score_spread":0.28764283801304896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380785062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390304,0.004414122,0.00011627052,0.0007043967,0.00014844314,0.0004592393,0.000005599152,0.00007906111,0.00016982996],"genre_scores_gemma":[0.9943508,0.002712058,0.000002732431,0.0027953065,0.00003542797,0.00006736798,0.000017483682,0.000008684806,0.000010160138],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99904966,0.00012738534,0.00013950071,0.0003283082,0.00012421292,0.00023094685],"domain_scores_gemma":[0.9996006,0.00017799663,0.000031154,0.000075036245,0.000017800092,0.000097453434],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001007548,0.00011523355,0.00020611058,0.00009241765,0.000057255358,0.00000676507,0.000024227396,0.00007825715,0.000028150453],"category_scores_gemma":[0.000120659424,0.00009328655,0.000043853615,0.00019605045,0.00012531196,0.00009800584,0.00003055542,0.00016853987,0.00001724565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025898695,0.00034967627,0.074350186,0.0003079446,0.00008077549,0.00012557922,0.00015375794,0.00047178796,0.001443964,0.0022380678,0.000005280236,0.8945743],"study_design_scores_gemma":[0.003704445,0.0004375304,0.98401195,0.00002457794,0.00008109157,0.000019700403,0.00005328361,0.0007090562,0.0000043799005,0.010338321,0.00052922085,0.00008642963],"about_ca_topic_score_codex":0.0000021452252,"about_ca_topic_score_gemma":0.0000060603757,"teacher_disagreement_score":0.90966177,"about_ca_system_score_codex":0.0000032944276,"about_ca_system_score_gemma":0.000013056218,"threshold_uncertainty_score":0.38041154},"labels":[],"label_agreement":null},{"id":"W4382995246","doi":"10.1177/17562864231182934","title":"Cardiac therapies for Duchenne muscular dystrophy","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Muscular Dystrophy Canada; Alberta Innovates; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Medicine; Duchenne muscular dystrophy; Dystrophin; Intensive care medicine; Disease; Bioinformatics; Cardiomyopathy; Exon skipping; Clinical trial; Muscular dystrophy; Genetic enhancement; Genome editing; CRISPR; Internal medicine; Heart failure; Exon; Gene","score_opus":0.03475826749725864,"score_gpt":0.3471559604144085,"score_spread":0.31239769291714986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382995246","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046618292,0.9964038,0.0005852372,0.00008075014,0.0005536257,0.0015666458,0.00009738767,0.000071990435,0.000174352],"genre_scores_gemma":[0.000857741,0.99641603,0.00010233157,0.00037161107,0.00021109285,0.0013855778,0.0004459374,0.000115186616,0.00009450026],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99717623,0.00045619937,0.0005346712,0.001042597,0.00012975365,0.0006605321],"domain_scores_gemma":[0.99877495,0.00030593525,0.00022199025,0.000596613,0.00002891029,0.00007162537],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025003208,0.00062159856,0.0013045201,0.00012437717,0.000117971795,0.000017740049,0.0006178036,0.0006624392,0.000017286244],"category_scores_gemma":[0.00013506437,0.00047601215,0.00091900816,0.0003040657,0.0003829817,0.000009611538,0.00015528327,0.00039106092,0.00002545111],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024541866,0.00013469548,0.000038460017,0.002138166,0.00025315455,0.0000021327805,0.000014350542,0.00013651802,0.000030747182,0.0008647399,0.000072657705,0.99606895],"study_design_scores_gemma":[0.00043469254,0.0008136891,0.00007328424,0.00014721822,0.00017582484,0.0000010822721,0.000024030804,0.000011206704,0.0000010338889,0.011203142,0.9866063,0.00050852034],"about_ca_topic_score_codex":0.000002870239,"about_ca_topic_score_gemma":0.000020678775,"teacher_disagreement_score":0.99556047,"about_ca_system_score_codex":0.000007803275,"about_ca_system_score_gemma":0.000069784626,"threshold_uncertainty_score":0.99976915},"labels":[],"label_agreement":null},{"id":"W4386928780","doi":"10.1177/17562864231195513","title":"A <i>post hoc</i> evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Jazz Pharmaceuticals; Teva Pharmaceutical Industries; Biogen; Sanofi; Jazz Pharmaceuticals Canada; Pfizer","keywords":"Spasticity; Medicine; Multiple sclerosis; Physical medicine and rehabilitation; Post-hoc analysis; Neuroscience; Post hoc; Physical therapy; Internal medicine; Psychiatry; Psychology","score_opus":0.05747565638420654,"score_gpt":0.3156648069380463,"score_spread":0.2581891505538398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386928780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413633,0.00092628546,0.000044675016,0.0019055497,0.000032131218,0.002591559,0.000024361178,0.00007368649,0.00026538898],"genre_scores_gemma":[0.9979099,0.001181389,0.000045933506,0.000344706,0.000007340769,0.00045598997,0.000018163804,0.000031130276,0.000005442113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960511,0.0009490691,0.00056734995,0.00061694114,0.0011449698,0.0006705999],"domain_scores_gemma":[0.99792916,0.0012778281,0.00019162138,0.00038772167,0.00013635389,0.00007734291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012127991,0.0003288245,0.0006390513,0.00036988093,0.00008385735,0.000012239228,0.00030855872,0.00014545501,0.000045753844],"category_scores_gemma":[0.0011245457,0.00018420671,0.00007112707,0.0025698398,0.00093024655,0.0001742236,0.000149532,0.00074120617,0.000005967187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020103308,0.00065795396,0.9428488,0.000062516454,0.000043085536,0.000008715319,0.000738175,0.03438066,0.0007483296,0.00003623409,0.0000012326676,0.018463949],"study_design_scores_gemma":[0.009772081,0.0015447123,0.9680806,0.00023263051,0.000068271496,0.000001926571,0.0004045608,0.01824061,0.00013485471,0.0013052938,0.000025664425,0.00018881637],"about_ca_topic_score_codex":0.00028285463,"about_ca_topic_score_gemma":0.007752549,"teacher_disagreement_score":0.02523176,"about_ca_system_score_codex":0.000080877064,"about_ca_system_score_gemma":0.00013233692,"threshold_uncertainty_score":0.75117314},"labels":[],"label_agreement":null},{"id":"W4386939132","doi":"10.1177/17562864231194823","title":"Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of British Columbia","funders":"Sanofi","keywords":"Medicine; Alemtuzumab; Multiple sclerosis; Relapsing remitting; Topaz; Open label; Oncology; Internal medicine; Adverse effect; Intensive care medicine; Immunology","score_opus":0.11936048497369685,"score_gpt":0.36085303580033307,"score_spread":0.24149255082663623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386939132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195164,0.00199226,0.000023494356,0.003266353,0.000072097835,0.0021653592,0.000030984753,0.00009606723,0.00040171156],"genre_scores_gemma":[0.9871072,0.011406926,0.00017145794,0.001048411,0.000036067522,0.00013667572,0.000018770035,0.000031862284,0.000042637435],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99696887,0.00052820204,0.00054016575,0.000839745,0.00051035784,0.0006126763],"domain_scores_gemma":[0.99504507,0.0042324904,0.00012252721,0.00048341192,0.000028452145,0.000088037785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009402552,0.00028100953,0.0005348386,0.00011289675,0.00020916738,0.00006203316,0.00047871665,0.000084516374,0.000018288498],"category_scores_gemma":[0.0015976254,0.00017178596,0.00003296084,0.00093193474,0.0004958171,0.00021923745,0.0005938313,0.0007894406,0.000009273414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01752405,0.0013908495,0.7048127,0.0000118042935,0.000068444955,0.00007018915,0.0027397245,0.0016998608,0.00018492399,0.000019355963,0.000033380544,0.27144468],"study_design_scores_gemma":[0.031068852,0.0018340829,0.95788956,0.0001688859,0.000026998894,0.0000014318668,0.0015612708,0.005286077,0.0000018446199,0.00028579487,0.0016880743,0.00018711836],"about_ca_topic_score_codex":0.00047337558,"about_ca_topic_score_gemma":0.003617405,"teacher_disagreement_score":0.27125758,"about_ca_system_score_codex":0.000035898724,"about_ca_system_score_gemma":0.00003745014,"threshold_uncertainty_score":0.70052284},"labels":[],"label_agreement":null},{"id":"W4390639097","doi":"10.1177/17562864231221324","title":"Tenecteplase for the treatment of acute ischemic stroke in the extended time window: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Heart and Stroke Foundation of Canada","keywords":"Medicine; Modified Rankin Scale; Tenecteplase; Odds ratio; Meta-analysis; Thrombolysis; Randomized controlled trial; Confidence interval; Internal medicine; Stroke (engine); Fibrinolytic agent; Relative risk; Tissue plasminogen activator; Ischemic stroke; Ischemia; Myocardial infarction","score_opus":0.051828240869509865,"score_gpt":0.37105878754380517,"score_spread":0.3192305466742953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390639097","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000058761493,0.98587304,0.00014169389,0.0018947168,0.000024465538,0.011512818,0.00017323504,0.00002789463,0.0003462603],"genre_scores_gemma":[0.00014133232,0.99050325,0.00009283976,0.0019215515,0.000012054782,0.00660828,0.00005622954,0.000039971525,0.0006245143],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99676967,0.00053610845,0.001247534,0.0007291902,0.00034816912,0.00036933494],"domain_scores_gemma":[0.99594754,0.0025194997,0.00049554795,0.00097386946,0.000022748314,0.000040822502],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000638516,0.00068370294,0.0064785914,0.00026902382,0.00003872188,0.000019139512,0.00052309217,0.00015939726,0.00006729472],"category_scores_gemma":[0.00009148979,0.00024776664,0.002617116,0.0010605075,0.00025709136,0.00004525651,0.00007424665,0.00038121018,0.00000850221],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018859551,0.0009914835,0.0000065868476,0.63610864,0.25556287,0.00008712769,0.00019240922,0.000013027686,0.0000010741144,0.00011825509,0.00022600821,0.10650393],"study_design_scores_gemma":[0.00036194723,0.0006866116,0.0000028339077,0.0023834177,0.7443034,0.000028792976,0.000025605308,0.00011483164,1.3375825e-7,0.00006128211,0.25187102,0.00016010078],"about_ca_topic_score_codex":0.000002966371,"about_ca_topic_score_gemma":0.0000073497845,"teacher_disagreement_score":0.6337252,"about_ca_system_score_codex":0.00004149328,"about_ca_system_score_gemma":0.000030907268,"threshold_uncertainty_score":0.99999744},"labels":[],"label_agreement":null},{"id":"W4391053875","doi":"10.1177/17562864231218181","title":"Effect of altered gene expression in lipid metabolism on cognitive improvement in patients with Alzheimer’s dementia following fecal microbiota transplantation: a preliminary study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Gut microbiota and health","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Research Foundation of Korea; National Research Foundation","keywords":"Dementia; Gut flora; Medicine; Montreal Cognitive Assessment; Cognitive decline; Feces; Transplantation; Microbiome; Clinical Dementia Rating; Internal medicine; Biology; Physiology; Immunology; Bioinformatics; Disease; Microbiology","score_opus":0.007089060045650178,"score_gpt":0.2823228089757372,"score_spread":0.275233748930087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391053875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98890346,0.009378644,0.0001511807,0.000031827294,0.00016291496,0.0013259959,0.000017686603,0.0000086530035,0.00001961011],"genre_scores_gemma":[0.9986607,0.00087914924,0.00004732066,0.00020055496,0.000015668196,0.000113458,0.000064248125,0.000018154955,7.452171e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984747,0.00034628203,0.00029998593,0.00049967144,0.00011344793,0.00026592202],"domain_scores_gemma":[0.99968934,0.000095638134,0.000053483902,0.00012418105,0.000008979278,0.000028382465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020375525,0.00021365439,0.00026354572,0.00010546917,0.000026135454,0.000008344811,0.000121536505,0.00009051417,0.0000059890117],"category_scores_gemma":[0.0000083841405,0.00015089531,0.00006102988,0.00016964615,0.0000566029,0.000013997155,0.000038279104,0.00019938288,8.430882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030952798,0.0037020056,0.54155743,0.0003221457,0.00035228874,0.000052406624,0.000989512,0.0013187324,0.26974738,0.000006974127,0.0000025052207,0.15099582],"study_design_scores_gemma":[0.0117989555,0.03204955,0.90727204,0.00024353115,0.0002805223,0.000001432991,0.00010415455,0.00006920953,0.04763653,0.00004582695,0.00014833389,0.0003498964],"about_ca_topic_score_codex":0.0000072909556,"about_ca_topic_score_gemma":0.0000791904,"teacher_disagreement_score":0.3657146,"about_ca_system_score_codex":0.000005111451,"about_ca_system_score_gemma":0.000018477102,"threshold_uncertainty_score":0.6153332},"labels":[],"label_agreement":null},{"id":"W4392157493","doi":"10.1177/17562864231221331","title":"Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Health and Medical Research Council; Sanofi Genzyme; Grifols; Všeobecná Fakultní Nemocnice v Praze; Sanofi; European Commission; Canadian Institutes of Health Research; Multiple Sclerosis Australia; Teva Pharmaceutical Industries; Univerzita Karlova v Praze; Medical Research Council; Biogen; Celgene","keywords":"Natalizumab; Medicine; Multiple sclerosis; Disease; Fingolimod; First line therapy; Glatiramer acetate; Clinical significance; Teriflunomide; Intensive care medicine; Oncology; Internal medicine; Immunology","score_opus":0.09250910395706537,"score_gpt":0.36120260786897235,"score_spread":0.268693503911907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392157493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831077,0.011551639,0.0006260621,0.0020874664,0.000083392704,0.002183543,0.000045388333,0.00023742962,0.00007736928],"genre_scores_gemma":[0.977885,0.019898303,0.00029507172,0.0013205044,0.00004207019,0.0004062331,0.000045538196,0.00009608681,0.000011157453],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959839,0.00039137845,0.0007146555,0.0011224729,0.0009324685,0.0008551087],"domain_scores_gemma":[0.9967231,0.002202411,0.00019533694,0.00053191,0.00011953967,0.00022767698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031566859,0.0006220154,0.0011828982,0.00028539723,0.00021176053,0.000099819954,0.0003429765,0.00012284295,0.000047765167],"category_scores_gemma":[0.00026409645,0.0003361497,0.0001531817,0.00080850156,0.0010449109,0.0005138965,0.00012401772,0.0010235269,0.0000054137595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015286553,0.001709092,0.8962026,0.00023428802,0.0002793455,0.00008799367,0.000408957,0.0016167515,0.0000017841558,0.000014181007,0.0000018239839,0.08415661],"study_design_scores_gemma":[0.01598152,0.0038828922,0.97475624,0.0012710715,0.000053074327,0.0000017106508,0.00016695893,0.003101618,0.0000018511894,0.00010954515,0.00023647727,0.00043706672],"about_ca_topic_score_codex":0.000024685936,"about_ca_topic_score_gemma":0.001711068,"teacher_disagreement_score":0.083719544,"about_ca_system_score_codex":0.00006180254,"about_ca_system_score_gemma":0.00007387856,"threshold_uncertainty_score":0.99990904},"labels":[],"label_agreement":null},{"id":"W4392848466","doi":"10.1177/17562864241233044","title":"Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society; Research Manitoba; Multiple Sclerosis Trust; Multiple Sclerosis Society of Canada; Arthritis Society; Alexion Pharmaceuticals; Celgene; Biogen; Gemeinsame Bundesausschuss; Sanofi; U.S. Department of Defense","keywords":"Medicine; Multiple sclerosis; Observational study; Fingolimod; Disease; Proportional hazards model; Patient registry; Internal medicine; Adverse effect; Pediatrics; Emergency medicine; Immunology","score_opus":0.17047351675556285,"score_gpt":0.3773027207272071,"score_spread":0.20682920397164425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392848466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97074026,0.02076002,0.002376575,0.0043291003,0.00018571463,0.0012138595,0.000035849873,0.00013783126,0.00022080533],"genre_scores_gemma":[0.9627179,0.035614703,0.000107552965,0.001007129,0.000045368968,0.00043041346,0.00003909962,0.00003358637,0.000004260318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976626,0.00023880997,0.00046396168,0.00060969574,0.0003944138,0.0006304922],"domain_scores_gemma":[0.9989127,0.0006566316,0.000042115134,0.0002657694,0.000022005159,0.000100771445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035227594,0.00025847947,0.00037088245,0.0004416218,0.00008378393,0.000037321475,0.00017123893,0.00010000769,0.00013442282],"category_scores_gemma":[0.00033652326,0.00020119591,0.000110831454,0.00084391126,0.00014080912,0.00036253748,0.000089724446,0.000645728,0.000013808705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058597623,0.0005331649,0.864364,0.00008742774,0.000010303023,0.000037459897,0.0002961959,0.0018393948,0.00019049873,0.0005017795,0.000001898592,0.13155186],"study_design_scores_gemma":[0.0026645327,0.00021755313,0.9172684,0.0002188897,0.0000070032734,6.02466e-7,0.000088338216,0.06878094,0.0000047522926,0.009493616,0.0010830202,0.00017236239],"about_ca_topic_score_codex":0.000098274075,"about_ca_topic_score_gemma":0.006586877,"teacher_disagreement_score":0.1313795,"about_ca_system_score_codex":0.00006993402,"about_ca_system_score_gemma":0.000034375982,"threshold_uncertainty_score":0.82045317},"labels":[],"label_agreement":null},{"id":"W4393121545","doi":"10.1177/17562864241239453","title":"Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisons","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Novartis Australia","keywords":"Fingolimod; Medicine; Cladribine; Ofatumumab; Teriflunomide; Placebo; Internal medicine; Multiple sclerosis; Natalizumab; Disease; Alternative medicine; Immunology; Rituximab; Pathology","score_opus":0.3913923956294829,"score_gpt":0.44032755044416655,"score_spread":0.048935154814683635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393121545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98065853,0.01556046,0.0014593048,0.000207673,0.00012983788,0.0018332824,0.0000381292,0.00007415519,0.000038628492],"genre_scores_gemma":[0.99218553,0.0062824325,0.0013471261,0.00007482656,0.000014552619,0.000042483574,0.000025820535,0.000022934184,0.0000043055165],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981806,0.00021853962,0.00040748293,0.00053402456,0.0002688462,0.00039050082],"domain_scores_gemma":[0.9975534,0.0019727442,0.000098072436,0.00019685566,0.000100189565,0.00007871877],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012695648,0.00030283746,0.000835597,0.00016403352,0.00015946725,0.0000292137,0.00009640715,0.00008122351,0.000011110559],"category_scores_gemma":[0.00020545622,0.00019726991,0.00016211893,0.00042763338,0.0006845208,0.00018263274,0.00007747671,0.00021885983,7.4645243e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024059428,0.0034392234,0.7361139,0.0003856405,0.0011435979,0.0000061631017,0.0036830537,0.023280468,0.017139161,0.0000821421,0.00001546517,0.19065171],"study_design_scores_gemma":[0.017338533,0.006349515,0.78646016,0.0003420265,0.00038450852,7.909912e-7,0.00044257657,0.18540888,0.0010883646,0.00027979142,0.001576955,0.00032789528],"about_ca_topic_score_codex":0.00007006162,"about_ca_topic_score_gemma":0.00017087892,"teacher_disagreement_score":0.19032383,"about_ca_system_score_codex":0.000058100133,"about_ca_system_score_gemma":0.00003736412,"threshold_uncertainty_score":0.8044433},"labels":[],"label_agreement":null},{"id":"W4393309179","doi":"10.1177/17562864241239101","title":"Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a <i>post hoc</i> analysis","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Serono Symposia International Foundation; International Progressive MS Alliance; National Research Foundation; Universität Basel; Celgene; Alnylam Pharmaceuticals; Teva Pharmaceutical Industries; Biogen; Sanofi; Merck","keywords":"Medicine; Post-hoc analysis; Multiple sclerosis; Confidence interval; Hazard ratio; Internal medicine; Proportional hazards model; Magnetic resonance imaging; Relapsing remitting; McDonald criteria; Placebo; Gastroenterology; Pathology; Immunology; Radiology","score_opus":0.031800728844806815,"score_gpt":0.37541925881852567,"score_spread":0.34361852997371883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393309179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98194903,0.0024241866,0.00017486836,0.012795463,0.000096491,0.0022368385,0.000008393543,0.000056017456,0.00025873547],"genre_scores_gemma":[0.994574,0.0030234687,0.000070098096,0.0018720399,0.000027981516,0.00038759463,0.000012310647,0.00002147746,0.000011027187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962944,0.00097531604,0.0007800767,0.000739134,0.00068948074,0.0005216388],"domain_scores_gemma":[0.99710745,0.0022975826,0.00009158332,0.00038621578,0.00004832566,0.00006887264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011748504,0.0002743845,0.0005810103,0.00044105097,0.00011525034,0.000037770893,0.0002966542,0.00008482029,0.000036642938],"category_scores_gemma":[0.00054009206,0.00015364961,0.00016178864,0.002532753,0.0002257691,0.00014974829,0.00013956107,0.0010739422,0.0000074824743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001313304,0.002449783,0.9286851,0.000039811133,0.00012793146,0.000059130027,0.0017243621,0.004292296,0.0000010353002,0.000050355888,0.0000044489207,0.061252393],"study_design_scores_gemma":[0.0031956034,0.0050556194,0.97533584,0.0000780224,0.00014458717,5.7527353e-7,0.0010193028,0.013240316,1.0809587e-7,0.00018658838,0.0015949635,0.00014850426],"about_ca_topic_score_codex":0.000027656653,"about_ca_topic_score_gemma":0.006135789,"teacher_disagreement_score":0.06110389,"about_ca_system_score_codex":0.000052216288,"about_ca_system_score_gemma":0.000043606087,"threshold_uncertainty_score":0.6265649},"labels":[],"label_agreement":null},{"id":"W4394896461","doi":"10.1177/17562864241243186","title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Chugai Pharmaceutical; Horizon Therapeutics; Genentech; Grifols; Mitsubishi Tanabe Pharma Corporation; Warszawski Uniwersytet Medyczny; CSL Behring; National Institute for Health and Care Research; Regeneron Pharmaceuticals; National Institutes of Health; UCB Pharma; Argenx; Cytokinetics; Japan Blood Products Organization; Union Chimique Belge; Alexion Pharmaceuticals; Patient-Centered Outcomes Research Institute; Biogen; Centers for Disease Control and Prevention; Muscular Dystrophy Association; Uniwersytet Warszawski; Momenta Pharmaceuticals; Sanofi; AstraZeneca; Myasthenia Gravis Foundation of America","keywords":"Medicine; Myasthenia gravis; Interim; Interim analysis; Open label; Term (time); Extension (predicate logic); Adverse effect; Clinical trial; Internal medicine; Law; Computer science","score_opus":0.02397615723265628,"score_gpt":0.329973967553128,"score_spread":0.30599781032047174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394896461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99495155,0.0031485532,0.00014771902,0.00025352315,0.00006314321,0.0013562632,0.0000116428755,0.000017521024,0.000050061095],"genre_scores_gemma":[0.99900067,0.00059357076,0.000049003786,0.00028266915,0.000004387436,0.000023075258,0.000014496411,0.000019433235,0.000012690855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981675,0.0002981884,0.0005379644,0.00048800226,0.00028560482,0.0002227012],"domain_scores_gemma":[0.9991699,0.00020147418,0.00013429581,0.00040996267,0.000035936377,0.000048458398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002465661,0.00022479019,0.00075185904,0.0002492988,0.000037522797,0.000017118484,0.00029957813,0.000062862164,0.000048463655],"category_scores_gemma":[0.000038389677,0.00011819281,0.00007639141,0.0011781807,0.00029964984,0.00010316702,0.00018793276,0.00026574286,4.599416e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008794877,0.0026707682,0.9211267,0.00005531693,0.00025981804,0.000016741391,0.00078583916,0.00032244643,0.00011245127,0.00019497794,3.1590773e-7,0.065659724],"study_design_scores_gemma":[0.009136248,0.0034454304,0.98475814,0.00012222164,0.00050749944,0.0000018268146,0.00008123776,0.0013322748,0.000005617285,0.00043704937,0.000051668012,0.00012076354],"about_ca_topic_score_codex":0.00002942948,"about_ca_topic_score_gemma":0.0002596849,"teacher_disagreement_score":0.06553896,"about_ca_system_score_codex":0.000011006151,"about_ca_system_score_gemma":0.000020299121,"threshold_uncertainty_score":0.4819763},"labels":[],"label_agreement":null},{"id":"W4396242288","doi":"10.1177/17562864241246938","title":"Overview of systematic reviews comparing endovascular to best medical treatment for large-vessel occlusion acute ischaemic stroke: an umbrella review","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Randomized controlled trial; Modified Rankin Scale; Systematic review; Meta-analysis; MEDLINE; Confidence interval; Relative risk; Stroke (engine); Cochrane Library; Internal medicine; Physical therapy; Ischemic stroke; Ischemia","score_opus":0.0994132575965261,"score_gpt":0.40835839606508734,"score_spread":0.30894513846856125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396242288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018978361,0.94756335,0.018197328,0.0044808434,0.00031813377,0.009247568,0.000026510843,0.00012373811,0.0010641519],"genre_scores_gemma":[0.14444715,0.8451055,0.0011858831,0.0078001237,0.00005711997,0.0011341353,0.00004416977,0.000047703474,0.00017821607],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966835,0.0003720543,0.001137672,0.00072609825,0.00058738666,0.00049328717],"domain_scores_gemma":[0.9983908,0.0005006705,0.0001737427,0.0006872291,0.000036995796,0.00021058605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011107776,0.0004119807,0.0018277459,0.00015319369,0.000051383857,0.000013244541,0.0004101246,0.00012426794,0.00016091885],"category_scores_gemma":[0.00033510945,0.00026075053,0.00046557657,0.0004568183,0.00008136974,0.00013570221,0.00017135627,0.00027213822,0.000034219298],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001603219,0.0045401566,0.005713086,0.57507235,0.0018403435,0.00058965397,0.0008850959,0.0002145822,0.0014538472,0.007351048,0.0021322602,0.39860436],"study_design_scores_gemma":[0.0047626044,0.0068834526,0.00039944416,0.09404774,0.004282683,0.0002015863,0.00017034229,0.020983145,0.00011151996,0.00063159567,0.86682105,0.00070485845],"about_ca_topic_score_codex":0.000005900026,"about_ca_topic_score_gemma":0.00003158482,"teacher_disagreement_score":0.86468875,"about_ca_system_score_codex":0.00007035574,"about_ca_system_score_gemma":0.000046883273,"threshold_uncertainty_score":0.99998444},"labels":[],"label_agreement":null},{"id":"W4402546531","doi":"10.1177/17562864241273045","title":"The Canadian Prospective Cohort Study to understand progression in multiple sclerosis: baseline characteristics","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hotchkiss Brain Institute; University of Manitoba; Providence Health Care; University of British Columbia; University of Calgary; Centre Hospitalier de l’Université de Montréal; University of Toronto; Women and Children’s Health Research Institute; University of Alberta; Centre for Advancing Health Outcomes; St. Michael's Hospital","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada; Michael Smith Health Research BC; Horizon Therapeutics; U.S. Department of Defense; Sanofi; Government of Alberta; Fondation Brain Canada; Teva Pharmaceutical Industries; Biogen; University of Toronto; Biogen Idec; Eli Lilly and Company; Arthritis Society; International Progressive MS Alliance; Roche; University of Calgary","keywords":"Medicine; Multiple sclerosis; Prospective cohort study; Baseline (sea); Cohort; Internal medicine; Oncology; Immunology","score_opus":0.057016722251758495,"score_gpt":0.3518034886168417,"score_spread":0.29478676636508316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402546531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758356,0.007280815,0.00020524868,0.009160329,0.00030636493,0.006207269,0.000018437244,0.00012253223,0.0008633608],"genre_scores_gemma":[0.99167204,0.0068245037,0.00006288067,0.00072835124,0.000048680904,0.00058947474,0.000005813936,0.00002984687,0.000038382943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736375,0.00035172477,0.0003997974,0.0006566848,0.0005249497,0.0007030873],"domain_scores_gemma":[0.99836224,0.0010088884,0.00003284707,0.00031422533,0.00006335948,0.00021841025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010397356,0.00025257064,0.00037886194,0.00025044626,0.0003140272,0.000102040634,0.00023137018,0.00006874452,0.00003023499],"category_scores_gemma":[0.0010901765,0.00015011335,0.000057868667,0.0008640711,0.00035412298,0.00012348712,0.00010914692,0.00070497574,0.000022231492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007580274,0.00045674437,0.84212947,0.000028292903,0.00003610653,0.00005770655,0.00093331886,0.00008334923,0.000039779618,0.00010795856,0.000016001799,0.15535325],"study_design_scores_gemma":[0.0010664869,0.0013969786,0.98460567,0.00012931692,0.000019762962,0.0000015754465,0.0012120446,0.0059766737,0.000004354561,0.0007815361,0.0046482463,0.00015737102],"about_ca_topic_score_codex":0.0015703789,"about_ca_topic_score_gemma":0.32217142,"teacher_disagreement_score":0.32060105,"about_ca_system_score_codex":0.00024530542,"about_ca_system_score_gemma":0.00014350317,"threshold_uncertainty_score":0.69019717},"labels":[],"label_agreement":null},{"id":"W4402546568","doi":"10.1177/17562864241273036","title":"Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"EMD Serono; Schweizerische Multiple Sklerose Gesellschaft; F. Hoffmann-La Roche; Grifols; Fondazione Cariplo; Multiple Sclerosis Society; UCB Pharma; Argenx; Idorsia Pharmaceuticals; Amicus Therapeutics; Janssen Pharmaceuticals; Merck KGaA; Bristol-Myers Squibb; CSL Behring; Pfizer; Biogen; Celgene; H. Lundbeck A/S; Alnylam Pharmaceuticals; Alexion Pharmaceuticals; Regeneron Pharmaceuticals; Novo Nordisk; Teva Pharmaceutical Industries; Sanofi","keywords":"Medicine; Myasthenia gravis; Autoantibody; Placebo; Subgroup analysis; Internal medicine; Tyrosine kinase; Gastroenterology; Antibody; Immunology; Oncology; Pharmacology; Meta-analysis; Receptor; Pathology; Alternative medicine","score_opus":0.015232509837930777,"score_gpt":0.2854096034517853,"score_spread":0.2701770936138545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402546568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876484,0.0059284726,0.00061653246,0.0001503535,0.00007181343,0.0053858655,0.000032012456,0.00003554343,0.00013099483],"genre_scores_gemma":[0.99887204,0.0007105936,0.000048405433,0.0000956515,0.000014190301,0.00018866111,0.000027101,0.00003392442,0.000009422717],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99696165,0.00047535432,0.0009424999,0.0007218453,0.0005068549,0.00039177874],"domain_scores_gemma":[0.9984641,0.0006432878,0.00028166836,0.0004447563,0.00008137063,0.00008478866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004435439,0.0004142287,0.0014987668,0.000543564,0.000078989426,0.00002335934,0.00024153816,0.000107100415,0.0000388474],"category_scores_gemma":[0.000029040197,0.00023298357,0.0002900789,0.0018748664,0.0004522602,0.00014741348,0.000093056835,0.0004660949,3.8505678e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8896889,0.0048258645,0.06220012,0.00004739364,0.0012457555,0.000047271493,0.0022052634,0.0057025286,0.00032286992,0.0009781475,2.8455895e-7,0.032735597],"study_design_scores_gemma":[0.537104,0.0047907424,0.444657,0.00014346566,0.0017533153,0.0000017391367,0.00035245033,0.010652576,0.000029943552,0.00023138184,0.000042025054,0.000241358],"about_ca_topic_score_codex":0.00005240164,"about_ca_topic_score_gemma":0.00018451104,"teacher_disagreement_score":0.38245687,"about_ca_system_score_codex":0.000032647946,"about_ca_system_score_gemma":0.000039593193,"threshold_uncertainty_score":0.95007944},"labels":[],"label_agreement":null},{"id":"W4402696194","doi":"10.1177/17562864241276204","title":"Exploring the association of disease-modifying therapies for multiple sclerosis and BTK inhibitors with epilepsy","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Collaboration On Repair Discoveries; University of British Columbia; McGill University; Montreal Neurological Institute and Hospital","funders":"","keywords":"Medicine; Ibrutinib; Odds ratio; Ofatumumab; Internal medicine; Epilepsy; Oncology; Adverse Event Reporting System; Population; Discontinuation; Adverse effect; Rituximab; Psychiatry; Leukemia; Lymphoma; Chronic lymphocytic leukemia","score_opus":0.07818901370015804,"score_gpt":0.3082756776405036,"score_spread":0.23008666394034558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402696194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772747,0.017673139,0.0007966526,0.0031025347,0.00012520855,0.0008726407,0.000007668567,0.0000666965,0.00008074988],"genre_scores_gemma":[0.9839596,0.01510401,0.00013899108,0.00031585348,0.000051452615,0.00037566441,0.000003510863,0.000025468873,0.000025413388],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987149,0.00010054066,0.00022158581,0.00032952602,0.00031720896,0.00031619647],"domain_scores_gemma":[0.997428,0.0022556644,0.00005275724,0.00017209978,0.000031327556,0.00006016441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034734068,0.00014890834,0.00023679821,0.000084360945,0.000078701785,0.00002663157,0.00010093127,0.000043653985,0.000006295142],"category_scores_gemma":[0.00023270003,0.00008203591,0.000074012016,0.00031063365,0.00026448735,0.00022681484,0.00004122673,0.00023348659,9.893108e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007907979,0.0003602041,0.3597562,0.0013024627,0.0002590995,0.000020957918,0.0026461296,0.0027435026,0.0010606436,0.0034536114,0.000017206023,0.620472],"study_design_scores_gemma":[0.03120102,0.005394804,0.7014284,0.0013293772,0.0005193353,0.000019211644,0.002377411,0.18686287,0.0008108579,0.029620504,0.039631743,0.00080444495],"about_ca_topic_score_codex":0.000014433204,"about_ca_topic_score_gemma":0.00005004484,"teacher_disagreement_score":0.6196676,"about_ca_system_score_codex":0.00027725374,"about_ca_system_score_gemma":0.00018585467,"threshold_uncertainty_score":0.33453274},"labels":[],"label_agreement":null},{"id":"W4402890485","doi":"10.1177/17562864241281903","title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"","keywords":"Medicine; Liraglutide; Semaglutide; Internal medicine; Mace; Overweight; Odds ratio; Diabetes mellitus; Type 2 diabetes; Placebo; Dulaglutide; Myocardial infarction; Population; Glucagon-like peptide 1 receptor; Endocrinology; Adverse effect; Obesity; Agonist; Receptor; Percutaneous coronary intervention","score_opus":0.06532569228572091,"score_gpt":0.3519981919897024,"score_spread":0.28667249970398145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402890485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027852592,0.9872574,0.00001538993,0.0002756531,0.000036422032,0.009388379,0.00016550692,0.00004407711,0.00003191655],"genre_scores_gemma":[0.004721816,0.990497,0.00008047996,0.0005613744,0.000009893245,0.00366509,0.00010009611,0.00006751413,0.00029672173],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.994672,0.0016898835,0.0013412673,0.0011868681,0.0005966389,0.0005133412],"domain_scores_gemma":[0.9972081,0.00080159964,0.0006573873,0.0011590355,0.00003659855,0.00013727449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008478959,0.0010426599,0.008182822,0.000290637,0.00006262141,0.000024731187,0.00023786265,0.00018707603,0.00012269965],"category_scores_gemma":[0.000107594125,0.00036152528,0.0018145065,0.0011444499,0.0003776384,0.00013368779,0.00015233544,0.0004130514,0.0000072188777],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004839648,0.0010341572,0.0036303534,0.35610968,0.61079574,0.00014248127,0.00015045493,0.000038353697,1.2806148e-8,0.000039667877,0.0000041108087,0.027570993],"study_design_scores_gemma":[0.0017863885,0.0022220411,0.00045315086,0.011460689,0.9659539,0.000008585625,0.00008439146,0.0000529376,5.9750185e-8,0.00012955062,0.017427027,0.00042130682],"about_ca_topic_score_codex":0.00008166599,"about_ca_topic_score_gemma":0.0012470324,"teacher_disagreement_score":0.35515812,"about_ca_system_score_codex":0.00010109142,"about_ca_system_score_gemma":0.000074836295,"threshold_uncertainty_score":0.99988365},"labels":[],"label_agreement":null},{"id":"W4403258165","doi":"10.1177/17562864241283328","title":"Clinical and ethical challenges in decision-making for patients with disorders of consciousness and locked-in syndrome from Chinese neurologists’ perspectives","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Traumatic Brain Injury Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"National Key Research and Development Program of China; Fonds De La Recherche Scientifique - FNRS; Natural Science Foundation of Zhejiang Province; Hangzhou Normal University; National Natural Science Foundation of China","keywords":"Medicine; Persistent vegetative state; Consciousness; Psychiatry; Minimally conscious state; Intensive care medicine; Neuroscience; Psychology","score_opus":0.039950785971992586,"score_gpt":0.3939442022738692,"score_spread":0.35399341630187664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403258165","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96664345,0.025846532,0.0006534808,0.0055016787,0.00009039881,0.0011195808,0.000015309355,0.000041365427,0.000088194945],"genre_scores_gemma":[0.97855884,0.020093026,0.00088155066,0.000320238,0.000011050726,0.00010246901,0.0000029905757,0.000029108289,7.3493334e-7],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753374,0.00037862148,0.00057221367,0.00083398254,0.0003112866,0.00037013745],"domain_scores_gemma":[0.98971283,0.009883148,0.000063423744,0.00023298667,0.000031413987,0.000076203556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006455962,0.00025342952,0.0007038427,0.00026907737,0.000030431134,0.000016419082,0.00016154292,0.0002987887,0.000018492196],"category_scores_gemma":[0.0012618408,0.00016636969,0.000065616616,0.00037052744,0.0014610963,0.00010905198,0.00009799079,0.0011055488,5.029583e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036476864,0.00045251998,0.66744524,0.00016695788,0.000021485623,0.000038374525,0.0008550266,0.000066887136,0.0000010324328,0.0008381075,2.7195998e-7,0.32646638],"study_design_scores_gemma":[0.0033409058,0.0033098918,0.8676956,0.00025723,0.000017630151,0.000007634619,0.0004525766,0.0047444915,4.90863e-8,0.119903065,0.00012698593,0.00014393062],"about_ca_topic_score_codex":0.000012951034,"about_ca_topic_score_gemma":0.00089505955,"teacher_disagreement_score":0.32632247,"about_ca_system_score_codex":0.000011653001,"about_ca_system_score_gemma":0.00003863005,"threshold_uncertainty_score":0.6784359},"labels":[],"label_agreement":null},{"id":"W4403721828","doi":"10.1177/17562864241284166","title":"The impact of different lifestyle factors on disability in multiple sclerosis at older ages: a monocentric retrospective study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Multiple sclerosis; Medicine; Disease; Central nervous system; Gerontology; Pediatrics; Physical therapy; Internal medicine; Immunology","score_opus":0.061238697300212044,"score_gpt":0.35909734275134975,"score_spread":0.2978586454511377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403721828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99223787,0.0046624686,0.000009602692,0.00058353704,0.000115232164,0.002162235,0.000020097923,0.0000729868,0.00013595409],"genre_scores_gemma":[0.98831177,0.011338424,0.0000027492908,0.000043365555,0.000021106163,0.00023507177,0.0000043154864,0.000027335327,0.000015852931],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706084,0.0005528044,0.0005028347,0.000708144,0.00055958744,0.0006157969],"domain_scores_gemma":[0.99633545,0.002982242,0.00007404414,0.00047334383,0.000031246534,0.00010367733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036474143,0.0003588676,0.00062714494,0.00013770536,0.00014799723,0.00002638959,0.00026419453,0.000085466905,0.00007079286],"category_scores_gemma":[0.0010091792,0.00017328426,0.00028017332,0.00078185,0.00077219383,0.00010323252,0.00020884171,0.00070175243,0.000005224862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015762405,0.003017276,0.9597197,0.000040791736,0.000103064966,0.000007707039,0.0011170432,0.00059083727,0.000192694,0.000022981878,0.0000058932314,0.033605736],"study_design_scores_gemma":[0.0020647426,0.0038036252,0.98819005,0.00007229304,0.000021995893,3.9005954e-7,0.00063636265,0.004214546,0.000027833208,0.0007859457,0.000038839138,0.00014334185],"about_ca_topic_score_codex":0.00016747485,"about_ca_topic_score_gemma":0.0012149111,"teacher_disagreement_score":0.033462394,"about_ca_system_score_codex":0.0003616216,"about_ca_system_score_gemma":0.000019488,"threshold_uncertainty_score":0.70663273},"labels":[],"label_agreement":null},{"id":"W4405574148","doi":"10.1177/17562864241306684","title":"Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance","year":2024,"lang":"en","type":"review","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Sanofi","keywords":"Multiple sclerosis; Medicine; Pathology; Neuroinflammation; Disease; Biomarker; Neuroscience; Bioinformatics; Immunology; Biology","score_opus":0.2637609567356469,"score_gpt":0.45250954053715475,"score_spread":0.18874858380150783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405574148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007033652,0.9944591,0.00003875378,0.0012161419,0.00025885412,0.0028480024,0.000045006545,0.00011600242,0.0003147621],"genre_scores_gemma":[0.026584446,0.97158265,0.00009980778,0.00023504949,0.00014918957,0.0012005336,0.000033398064,0.00006814023,0.000046809902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951848,0.0009824397,0.0012708871,0.0014752749,0.00032430547,0.0007623264],"domain_scores_gemma":[0.99602664,0.002949782,0.00025778235,0.0005600932,0.000038074304,0.00016764185],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00051297876,0.0006365855,0.002321351,0.00045013655,0.000099981684,0.000027688884,0.00040430034,0.0006144161,0.000035945966],"category_scores_gemma":[0.0010309513,0.0004266378,0.00040422293,0.0008446115,0.0018407359,0.00014290905,0.00033009236,0.002602548,0.000056628454],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014553627,0.00035506103,0.0041453782,0.0032573787,0.000106665335,0.000028902832,0.000036743255,0.0000031442514,0.0000029339271,0.00009636147,0.00001604113,0.99180585],"study_design_scores_gemma":[0.0018244548,0.0012897489,0.13323984,0.005922915,0.00054047775,0.000014337876,0.00010545373,0.00072139653,2.1411792e-7,0.0010645387,0.85477144,0.00050518074],"about_ca_topic_score_codex":0.000014305679,"about_ca_topic_score_gemma":0.00058378885,"teacher_disagreement_score":0.9913007,"about_ca_system_score_codex":0.00016374196,"about_ca_system_score_gemma":0.00029114797,"threshold_uncertainty_score":0.99981856},"labels":[],"label_agreement":null},{"id":"W4411506045","doi":"10.1177/17562864251346326","title":"Therapeutic options for Duchenne muscular dystrophy: hope or hype?","year":2025,"lang":"en","type":"editorial","venue":"Therapeutic Advances in Neurological Disorders","topic":"Muscle Physiology and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Medicine; Duchenne muscular dystrophy; Muscular dystrophy; Intensive care medicine; Neuroscience; Physical medicine and rehabilitation; Internal medicine; Psychology","score_opus":0.009820308100301598,"score_gpt":0.3000819553959397,"score_spread":0.2902616472956381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411506045","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020730678,0.1758367,0.038316965,0.00334157,0.7491851,0.0075731324,0.0013844679,0.0003886896,0.0032427092],"genre_scores_gemma":[0.3039654,0.3615964,0.0027607507,0.012539724,0.29701632,0.0070034377,0.00841083,0.0005820002,0.0061251367],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663574,0.00038448544,0.00055248354,0.0013520373,0.00026868228,0.00080657226],"domain_scores_gemma":[0.99800104,0.00076935964,0.0002232865,0.00078991026,0.00012505951,0.00009137344],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00026043272,0.0006943071,0.0007332028,0.00014739002,0.00021443855,0.000033357366,0.0009073979,0.0014218478,0.000073155454],"category_scores_gemma":[0.00066445465,0.00054392626,0.0004228545,0.00028719445,0.0005252668,0.000017926317,0.00020834111,0.0008375743,0.0000066706684],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059838243,0.005224438,0.00096260157,0.0022343877,0.0018973043,0.00004660712,0.0001538535,0.023473028,0.011118932,0.008110185,0.3745474,0.512393],"study_design_scores_gemma":[0.0023304836,0.002421776,0.00026868065,0.000028066532,0.00012882086,8.490869e-7,0.00003370164,0.00016329059,0.000036661706,0.020355482,0.97361726,0.0006149261],"about_ca_topic_score_codex":0.000011437957,"about_ca_topic_score_gemma":0.00024847954,"teacher_disagreement_score":0.5990699,"about_ca_system_score_codex":0.000017077266,"about_ca_system_score_gemma":0.000284668,"threshold_uncertainty_score":0.99987453},"labels":[],"label_agreement":null},{"id":"W4412808922","doi":"10.1177/17562864251351760","title":"Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Rheinische Friedrich-Wilhelms-Universität Bonn; University of Alberta; McGill University Health Centre; Merck KGaA; McGill University","keywords":"Cladribine; Multiple sclerosis; Medicine; Relapsing remitting; Fingolimod; Oncology; Internal medicine; Immunology","score_opus":0.0542154939765968,"score_gpt":0.3566189088339214,"score_spread":0.3024034148573246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412808922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98638797,0.008344567,0.0003173414,0.0023181022,0.00022821264,0.0019971896,0.000012945815,0.000041006795,0.00035266465],"genre_scores_gemma":[0.97534186,0.023294607,0.00031054666,0.0008833643,0.00002652475,0.000110119625,0.000004564057,0.000014021906,0.000014370783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968797,0.0009301972,0.00080841646,0.00066690316,0.00033224022,0.00038255498],"domain_scores_gemma":[0.9901758,0.009137514,0.000123349,0.00046117074,0.00004183784,0.000060323484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090195006,0.0002343529,0.00067993056,0.000120908,0.00008985838,0.000013618903,0.00026340276,0.00012487177,0.000008876074],"category_scores_gemma":[0.0054775747,0.00014587231,0.00008742088,0.0005551076,0.0007270163,0.0000784536,0.00028024294,0.00078276085,0.0000020579137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055234637,0.0015677939,0.854551,0.00007520602,0.0000700546,0.000017047669,0.00042258302,0.00008539348,0.0007296333,0.00020288937,0.0000109780385,0.13674395],"study_design_scores_gemma":[0.013788319,0.0017929135,0.9744524,0.0003264572,0.00006631163,2.454815e-7,0.0006763583,0.002658235,0.000032682045,0.0057706498,0.00032410122,0.000111379304],"about_ca_topic_score_codex":0.0001564899,"about_ca_topic_score_gemma":0.0010969875,"teacher_disagreement_score":0.13663258,"about_ca_system_score_codex":0.000014895684,"about_ca_system_score_gemma":0.000029163502,"threshold_uncertainty_score":0.6557564},"labels":[],"label_agreement":null},{"id":"W4413436594","doi":"10.1177/17562864251360913","title":"Platelet inhibition strategies in rescue stenting after failed thrombectomy: a large retrospective multicenter registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Population Health Research Institute","funders":"Freiwillige Akademische Gesellschaft","keywords":"Medicine; Retrospective cohort study; Intensive care medicine; Internal medicine","score_opus":0.006398649536665043,"score_gpt":0.27690314426865786,"score_spread":0.27050449473199284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413436594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797536,0.014111948,0.0021099155,0.00063243625,0.00013520686,0.0007583567,0.000009602033,0.0001060503,0.002382843],"genre_scores_gemma":[0.9920252,0.0054446715,0.000077189485,0.002185493,0.000028050817,0.0001549346,0.000018139523,0.000020114701,0.000046214333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980072,0.00025943844,0.00039171093,0.0005917033,0.0002434176,0.00050655566],"domain_scores_gemma":[0.9994116,0.000102757826,0.000063423395,0.00033815118,0.000034175566,0.000049920756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002548336,0.00027299413,0.00053682807,0.00018413781,0.000066128094,0.000035360477,0.000111360074,0.00018509422,0.00013293],"category_scores_gemma":[0.00007407714,0.00021994105,0.0002435698,0.0005258228,0.00023069012,0.00034627935,0.00006479612,0.0005758331,0.0000071703485],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008059051,0.0012145631,0.95202005,0.0002273866,0.00017668078,0.0005946088,0.00039630098,0.00074443064,0.00031318865,0.0031745057,0.000006274387,0.033072937],"study_design_scores_gemma":[0.008316879,0.00033868165,0.9674031,0.00024216462,0.00006608322,0.000005965617,0.0012082522,0.0009931517,0.00009497023,0.016917033,0.0041617053,0.00025201056],"about_ca_topic_score_codex":0.000012344605,"about_ca_topic_score_gemma":0.00035444746,"teacher_disagreement_score":0.032820925,"about_ca_system_score_codex":0.000048706264,"about_ca_system_score_gemma":0.000052415326,"threshold_uncertainty_score":0.8968936},"labels":[],"label_agreement":null},{"id":"W4415736281","doi":"10.1177/17562864251388019","title":"Open-label study of efgartigimod in seronegative myasthenia gravis","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Argenx","keywords":"Myasthenia gravis; Disease; Clinical trial; MEDLINE; Multiple sclerosis","score_opus":0.03148259894330482,"score_gpt":0.37144689508051537,"score_spread":0.3399642961372106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415736281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98879117,0.0019691854,0.00020247558,0.0012525761,0.00008173334,0.0017332758,0.0000024765704,0.000029437835,0.005937648],"genre_scores_gemma":[0.99738675,0.00062964833,0.00016479015,0.0015050079,0.0000057061284,0.00015911377,0.0000025482952,0.000015024718,0.00013140027],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980835,0.00029020873,0.0005487961,0.0005169162,0.00021304745,0.0003475635],"domain_scores_gemma":[0.9991535,0.0002650343,0.00011278439,0.00038364233,0.00003393882,0.00005109164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026032716,0.00023544667,0.00065840344,0.00023131074,0.000043305896,0.000014173596,0.00046601772,0.00009322924,0.00006257699],"category_scores_gemma":[0.00007811396,0.00017609804,0.000041152412,0.0008920021,0.00021045076,0.00015600924,0.00022781154,0.00040295237,0.0000045670236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065757562,0.017081674,0.6966794,0.00009128068,0.000073581396,0.00006995174,0.0015679782,0.000464787,0.00043138576,0.0124458,0.0000076287506,0.26451072],"study_design_scores_gemma":[0.028175568,0.008716476,0.82530135,0.00012847043,0.00007659953,0.000004624286,0.0019271376,0.0020529437,0.000072125156,0.1294898,0.0037546505,0.0003002731],"about_ca_topic_score_codex":0.00007203512,"about_ca_topic_score_gemma":0.0006822859,"teacher_disagreement_score":0.26421046,"about_ca_system_score_codex":0.000017265855,"about_ca_system_score_gemma":0.00004055193,"threshold_uncertainty_score":0.7181069},"labels":[],"label_agreement":null},{"id":"W7116706400","doi":"10.1177/17562864251406032","title":"Regional perfusion parameters as potential indicators of parenchymal hematoma risk following reperfusion therapy for acute ischemic stroke in the extended time window","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Acute Ischemic Stroke Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"State Key Laboratory of Medical Neurobiology; Science and Technology Commission of Shanghai Municipality; National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Reperfusion therapy; Stroke (engine); Ischemic stroke; Perfusion scanning; Parenchyma; Perfusion; Ischemia; Reperfusion injury","score_opus":0.00823023003550447,"score_gpt":0.2940993371725928,"score_spread":0.2858691071370883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116706400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869069,0.004402423,0.0017929949,0.002799687,0.00014748504,0.0019181052,0.000010807523,0.00005211028,0.0019694925],"genre_scores_gemma":[0.987509,0.007306997,0.0010090785,0.0036949103,0.00001880083,0.00026881925,0.000031276235,0.000021915414,0.00013921742],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975465,0.00025433095,0.000603252,0.00063845655,0.00048516493,0.0004722778],"domain_scores_gemma":[0.9985276,0.0006565429,0.00025978836,0.00048640175,0.000022555892,0.00004711771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005380254,0.00032717784,0.0005863062,0.00035080657,0.00010855989,0.000013192163,0.00048584325,0.0001934584,0.00004305874],"category_scores_gemma":[0.0001518839,0.00021569798,0.0003622993,0.00063833944,0.00029423359,0.00012476095,0.00011721568,0.000526068,0.0000030930007],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018485934,0.0026164968,0.19528969,0.00011783797,0.0006315588,0.00015111835,0.0011646418,0.0010238376,0.044150192,0.0005836623,0.0007512327,0.7350338],"study_design_scores_gemma":[0.08364299,0.02126394,0.6413058,0.0010976926,0.003510548,0.00019434678,0.0070871706,0.031438068,0.025204878,0.037764013,0.14461584,0.0028747362],"about_ca_topic_score_codex":0.000012760953,"about_ca_topic_score_gemma":0.0000034261707,"teacher_disagreement_score":0.7321591,"about_ca_system_score_codex":0.000030642266,"about_ca_system_score_gemma":0.00005223793,"threshold_uncertainty_score":0.8795908},"labels":[],"label_agreement":null},{"id":"W7117165888","doi":"10.1177/17562864251399595","title":"Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase Registry","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Montréal","funders":"","keywords":"Retrospective cohort study; Horizontal and vertical; Disease; Prospective cohort study; Stability (learning theory)","score_opus":0.04490933011687496,"score_gpt":0.34399487146628144,"score_spread":0.29908554134940646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117165888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934355,0.0035621168,0.0005673503,0.0005798223,0.00006444707,0.0012357425,0.000035960387,0.000033446388,0.00048563158],"genre_scores_gemma":[0.9940344,0.0055806865,0.000069504466,0.00009513789,0.000011095302,0.00018084502,0.0000069716384,0.000015148768,0.0000062102645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704033,0.000899988,0.000593757,0.000574183,0.00047956922,0.0004121698],"domain_scores_gemma":[0.99635977,0.0026886524,0.00022784116,0.00058445433,0.00007727997,0.00006201226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076304586,0.00026949117,0.001070169,0.00064491783,0.000108735694,0.000009021316,0.00039047687,0.00008353417,0.000009270349],"category_scores_gemma":[0.0010428338,0.00017719515,0.0003722008,0.003395689,0.0006733374,0.00012480926,0.00022740416,0.0005925748,1.9511062e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023899202,0.0004259845,0.96769875,0.00031537926,0.0005251719,0.00000292147,0.00027233214,0.0014812703,0.005219669,0.00052331627,2.801317e-7,0.021145029],"study_design_scores_gemma":[0.0024252813,0.00023153359,0.98769367,0.00050718285,0.0003877913,4.8331263e-8,0.0002383106,0.0028622975,0.00039021941,0.005115233,0.000021136244,0.00012729295],"about_ca_topic_score_codex":0.00038482732,"about_ca_topic_score_gemma":0.0021408775,"teacher_disagreement_score":0.021017736,"about_ca_system_score_codex":0.00011051954,"about_ca_system_score_gemma":0.00007035311,"threshold_uncertainty_score":0.72258085},"labels":[],"label_agreement":null}]}